var title_f33_56_34688="Clindamycin: Pediatric drug information";
var content_f33_56_34688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=see_link\">",
"       Clindamycin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/21/38229?source=see_link\">",
"       Clindamycin (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13167 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34688=[""].join("\n");
var outline_f33_56_34688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=related_link\">",
"      Clindamycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/21/38229?source=related_link\">",
"      Clindamycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34689="ACL graft sites PI";
var content_f33_56_34689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Grafts used to replace torn anterior cruciate ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34689=[""].join("\n");
var outline_f33_56_34689=null;
var title_f33_56_34690="Child Down syndrome PI";
var content_f33_56_34690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child with Down syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows a child with Down syndrome who has some of the features common to the condition. These include a flat face, a flat top part of the nose, and an open mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34690=[""].join("\n");
var outline_f33_56_34690=null;
var title_f33_56_34691="Butoconazole: Patient drug information";
var content_f33_56_34691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Butoconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/23/40306?source=see_link\">",
"     see \"Butoconazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gynazole-1&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Femstat&reg; One;",
"     </li>",
"     <li>",
"      Gynazole-1&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to butoconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Condoms or diaphragms may not work to stop pregnancy. Use some other kind of birth control while taking this drug and for 72 hours after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have many vaginal infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. For vaginal use only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11583 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34691=[""].join("\n");
var outline_f33_56_34691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143806\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143807\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018839\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018838\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018843\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018844\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018846\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018841\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018842\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018847\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018848\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/23/40306?source=related_link\">",
"      Butoconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34692="Iloprost: Patient drug information";
var content_f33_56_34692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iloprost: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     see \"Iloprost: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ventavis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high pressure in the lungs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iloprost or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing into the lungs only using the I-neb&reg; AAD&reg; system or Prodose&reg; ADD&reg; system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After the last dose is used for the day, get rid of any drug that is left in the chamber so it is ready for the next day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11540 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34692=[""].join("\n");
var outline_f33_56_34692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181868\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013711\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013710\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013715\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013716\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013718\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013713\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013714\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013719\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013720\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=related_link\">",
"      Iloprost: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34693="Nissen fundoplication";
var content_f33_56_34693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51213%7EGAST%2F78957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51213%7EGAST%2F78957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Nissen fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 411px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGbAdEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACioJ7lIgSTWJqGtiMEKaAN2WeOMfMwqhNq8KZwRXG6hrpAJdsVjNqc85PkRO3ueBQB30uvop4NV38R46Vw4N0ctLIiew5qJ5Ap+a659hQOx3DeI27Ck/4SNx1BrhhMna6/WpFeU8x3AP40BY7hPEozzVuLxHE3WvOzd3Ef31VxTo7+Njh1aNqLhZnpkWu27Hk1bj1K3cffFeYCU4DI+4UovZBIihjyaBHqyzxt0cU8MD0NeZjWZYc/MeKuWXiKfYHYnDdKAPQaK5S38ScDzMVr2+swS4yQDQBqUVDHcxSfdYVMCD0NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUdKACs+/1BIQQDzUWq6kkCFVPzVzFzclw0krYUc80ASX+ou5b5sL3rnLq5e4crB07uf6U24ujeSlUGIR696ikk2gKnT1pNlJXEKwwfPMQ7+rVFJeXM/wAlrFtX+83Ap6wh2DuQKfLewwDCkZ9TUOaRvGjKWxHFpbzc3NxK/svApz6ZDGcLBEfd5CazrjXogxXezn0H/wBaoBrMp5itnb/gH+NQ60TpjgKj30NCW0AHFvaN7bjVR4THybJgPWKTNRnXpxw9m3/fApf7dtzxNAYz64K0e2Q3gKi2BZl3AedJE392Yf1q2RlR5igg9CORTYr23uFGx1ZT2fmpUtkGfIPlE/w5ypqlJPY550Z0/iRFho+Ym49KkhuA1wm7gg0yRdh6bXHUdj9KI1WYZ49jVXM3DS5LdSZRsGpt2yOFM4wgqlMCAVb8DUl2Ssif7tUZNE3nlpYow3U5P0qY38kcrEMcDpWZatuvHb+4n86hnlzMR70xWOostclUr8x5OK6Oz184AY153bHN1EvZQWrSaUjGD2oEel22sRyEAsOa0Y7mOQcMK8osrtxI7knC8VoQay6NwxoA9NBB6GiuOsddbaCx4rctdXikAyRQBq0VHHNHIMqwqSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzNWvxbxMAeas31ysEROea4jUrxriU88UANeZrmcs54rE1W7N1cGCE4hQ4J/vGrGrXJtbJQh/ezHaPpWShWJck8Dkmk3YqEXJ2RPNIltDz+A9ay5b8s2T17AVTvLxp5Gck7R0H9KqSOyQmRvvHgVy1Kt9j28NglFXluX7zVPKTBOXPQCsO6uyfmuZCF/uLVPU75LSNpZWG7HX0rL0nS9R8STGRy0Nnn8WFY3cj0IwhSVktS3P4mht28u1QF+m1Bk1WfW9auD+5s5cepJrvNH8KWFlDE0cCliQCSK6JdNjiu0VYwFZPSgly+R5XpMmv32oQ23kMrSHAbJ44zWlr13qfh9I/7Wi+R228rnFej6VbrBqyttHySqRx0qx8StPhu7eMTxhkEiNz+K/1rzcRi50sTCn9mRnKrJTUe55Tp+q2F6Ay5hf8Avxnj8RW9bXk1tglxNEe4rm/EXgxoGkudIYxsgBKjvWZoGszRzm0vQUlXgg9D716XmjXSfuyR6Ol4kigs3y9s9qhaX7PJvXmIn5h6e9YwkCjI/wBW3X2piXDqWiZiR2z3FWqr6nO8Er+6dXKyyw7lIOBnNRzPvSF/VcVzFnqUkEhiZsqOR9K2YLoOgUHjORW9OqpHm4nBSpK/Qt2g/e3LfSqkmPNJ96sWUmXuQfY1VuhzmtjgasWrBt17MfRABVyeULK49OKoaX/x8Tn/AHafdN+9lOe5oEkWoJv9B3d3Y0iSc1XiP+gW49if1p8Y+cUBY2wxSBADyaSK9kSYKCeOtV5ZMbRntUVuwZ5GPrii4OJ0drrEkRzu4ro9P10OoEleeSSYIANWYrhl+61MVj1aC5jmAKMKmrzSz1WaJgVY102meIVcBZzz60COloqGG5imUFHBqagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhuphDGSTUrEAEmuT8SansG1T3xQBX1y/LI+D3xXPxuXfNGoTloohn7zZNQQyhTk9OtA0rmdrNyr6qBnKwrgD3rJvrpnhEanlzz9KqTXJkvLh85yxqa3jMtyqt0XArkq1LuyPbwWGUIqciMx/6RDbrzgbn+p6VV1WdRIwB+WP5R9e5q5ayDddXR65JH4cCuU8Q3ZitwgPzStsz6Z71h5HprTV9CHTNNfxDqRuJc/wBnwtgf7Zr1jSLWOGV4IlCoEGAKwNDsVstINsgxsUH68Zrp9M/4/YG7PHRe7Inorvcu20H+idPuv/Wte4twJbZ8eoqrbDMNwvo2a1pQGtIX9CDW0UefUm7mFMgjv2I6lQfyqz47XzNHkYf889//AHyQ39KZqC4vgfVSKu67H9p0FF/vwsn5oRXz2de5OlU7P9UVJ6wkcJcHlvR4Qa5DxLogv0E9sAt0i71I74rrj88Nm/8Afhx+lVLUD7RAD0IKmvZvZnpWUonG6Hei4t2Rv9ZGdrA9j3FXLgFUVwc7T+lc9ev/AGX4z1O0HClw4+jAH+tb8MgntXHtVNWCE+bUp3zeXcRSj7pOD+NWjctCI5AcANzVTUBusAR2Gfypk5L2XHcZpLQuUU00zqtMug9/ICfvx1YuAcYrkbC8aOS1lzx9010VpdidWDn5lrrp1L6M8PF4Nw96OxdsSVnnHsDRcP8AvZhSWjhrl8fxJUMjZunB7it7nmWaZcjb/Q4PpTLi+gs4/MuZVjX3PX6etY2q60mn2qRrh58cKei+5rir67nvZjJO7Ox9e30oSubRp3R2OpeNYkJWzhMhH8chwPy//VXPXHinUpSds/lKe0agfr1rNgsZJjxWrbaAz4zVqKLskZkuqXkxzLczv/vOTVczSMckk/WuttvDAc4Jq03hDjg1QXRxKzup4JFWoNUu4DmG5mjPqrkfyrdu/DEsQJAzWNcac0RwwoDRm3pnj3XbAjy793UfwygPn8Tz+td3oXxnnj2pq2nRyr3e3cqR+Bzn8xXjr25FREMlKwnTiz6l0f4leGdTKp9uNpI38N0uzH/AuV/WuvhljmiWSGRJI2GVZDkEexr4tWdl61taD4p1XRJA+l389vzkorZRvqp4P4ilZGcqPY+u6K8X8NfGfLRxeILEbehuLbt7lD/Q/hXrGi6zp2t2guNKu4rmLvsPK+xHUH60mrGLi47mhRRRSJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg9KKZI+1WzQBR1S7EUDc815xrlyZZV54L10PiC9ySimuTv+Yt391gaAHXjAC3BPrWbcXoXzAp+6pNP1i5CJFjrg1hBy1vdOf7uK56tS2iPTwWF5/fkVNMQyuCe5zWpC3lLNJ/dVj+lVNHXam70Bou5wmm3Jz1Q1y+Z7VvslQS7NNOT94D9ea4bxXd48sg/dcEfnW5qGoLFaqu7HA/lXHTwXmv3RTT4WkSPl36Kv1NVBdSKs9Gl1Pd7VQXXH3ZIgf0rT0s4+xt6EqawdBmaTSNMkfG9YlRiPUDB/lW1aNtX/dlqVuVPVHRWfE1yvrg1orJnTFPp/jWZati+k90BqWGTOnzJnlSwraLPPqQuyPU2/0qAjvkfpWmSDosDNyFbn86xrx932U+4/lWvAPM0GQD+Fq8HPo81BPz/RlTVox9Tz6JCtjar3jZkP4EiqcfyzxH0c1rXAWNbpSQMXMhGfQnP9ax5JYllBMqD589a9OEueKl3R6NN3iecfFuGW28XLeW0blWt0Z2UHAOSOfwAqHQ9bSSP73JHIr0O+uIn8RRSI6sjQbW9OCf8ax9e8B6fqha60qQWN31wg/dsfcdvwrfmTVmYuEoPmj1MkXUc1gVzzgii2YPZoM9VqgvhLxXawsx0x7qJerWzrI3/fIO79KqW13LbMILmOSKVOCkilWH1Bpcq6FwxCbszRjz9jfHVGyPzq9a3RS8GDwy5rNs50dZlJ+9Ulu2ZYDn2pbGrSklc6Oz1ARXcZY/eO2maxqPkzkp1ArFv3MbxsOzA1VvZmllmJPQgD8q6KM3J2Z5mMwsYvnRUuJXuJmZ2LMxyTVm3hRQGkNUlYIcntUU1wznAPFdiZxNdDfiv4LccY4qUeIVXpXLBWal8o+lF2HLE66HxPtP3q0ofFQYD5hXnxQ1GdyngmjmYuRM9Tj12OdcMRWZqckUvK4rhIrqWM8E1ZXVJAMMCaakhez7GvMq9qrtAG7VUtLvzZ2LnAxwK3bREkx0qk7iasYstnnoKqSQsh6Gu0FhuHAqG60dtudtFhXOODMtaOja3faRdrc6ddS204/ijbGfY+o9jUl5p7Jn5aypomQ9KQPU998CfFyC7Edn4m2wzHhbxRhG/wB8fw/UcfSvW43WRFeNlZGGQynIIr4kSUqa9A+HnxEvvDEyQSlrrSmPz25PKe6Hsfbof1qWuxjKn1R9O0Vm+H9c0/X9PW80q4WaE8HsyH0YdjWlUmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABnmszV7kQxsM84rQlO35q43xHeZuCoPFAHN3VwZZTk9Caq35AspiewzTS2Ltwemc1T1q4/cSxg8lTUylyq5rRpupNRRkarOZSg9KgI26XcMe/FV/M81EbOflFWZv+QTKPauCTu7n01KHJBRHaf8tsx/2TWDrN2Fs5Vz1FaYnEVixz/Ca4jU7t538qPLOxwAO5oirhOVmNsNOufEmpi0iLJbRgGaUfwj0+pr06HTLTS9JFpZxLHEBwB1J9Se5qLw3pkej6ZHbxgGU/NK/wDec9f8Kv8A9mTX7jfM6p6IMfrSk76IcIKPvS3M3Qb22t9DjW4lVGSRhgntuNa1vrFjIXWO4TlgRzWhYeELWJdy2qsT3f5j+tWrjwrbsn7yyiI9dop8rE60L2bLFrexPeKyOpBTHX3qxDJj7Unvn8xXI6loc1j+90uRkZf+WTsSrewJ6VLout74Znmykija6t1Uii5Lpp6o3by8ihs4ZJGAC4PJpmmeKJp7KeCys/MDOcTSHamMDp3Nczp6Nrkplu8/YI2widPMPqfau30izjfCgBVUfgBWNbDwxEeSorompGEY+8cxP4fa/uZJ724lcyHJji+RemPr29akTwxYRj5rNSf9rJ/nXbSvBCNsSgkd6p3MrS9sVsoRglFdCI1pS2VkcpJ4esl+ZbOMe4GKatpHbZESbfxro3LYx2qjPFnNJm8ZPqZ0N1JbyB43KsO4Na8lzpmvW4tdfsILlQMKzLyPoeqn6Gsa4hINVwShrKUFLXqOpRhVWpzvj/wGujWM2qaDHd/ZosNLDKM7Vzywbrgeh/OvPrC9yYyT0avoDR9XK/uLt90DDb8wzge/tXO+MfhBFdwSaj4UdIbj75syf3bn/ZP8J/T6UoVWnyVfvOVzeHaUmedai4eEMDVSXi7IPSRAR9RVW4e5sppbLUIZLe5i4eORcEGrd6pe1hnj++gzXVB8kkzoqWr03Yz7lSMioIxzV5ys8e9O/wClVCu013Hk+RagAI5qfyhiqJk2jirdtMGUZNWmZuINDUTQ+1aIAIprIKYGYYKieHFarIPSoXQUrBcySGRsjqK0bDU2icBjxUcsOapyR7TU6orR7nfaXqivjJzXS200VwgBxXkdpdyW7cHiuq0fVshcNz6VadzOULHXahpCSxFkHNcTqunGJiCK7vTtSWRQGOQaXVtPiuoS6AZ9qZmnY8iuYChOKrrIUNdPqtiY5GGK525gKk4pNFnR+DPFd/4a1JbvT5ODgSxN9yVfQj+vavpvwZ4osvFWlLd2Z2Sr8s0BOWib+oPY9/zr47jco1dP4T8RXuganFe6dLskXhlPKyL3Vh3FK1zOdO59eUVkeFtetPEejw39i3ytw8ZPzRv3U1r1BzbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBR1ecQWzEmvO9WnMk3mZ4Bwa6vxTcZjaMdxXFofODI/BPH40AUtQbygk3boawLq4868X+6eK1tWmBtTEep4/GuZif5wT1U4rlry6I9jLaNrzZDbcIynqrFf1q6Pm0+4X/ZqrINmoXSdt24fjVu35hnX1U1zHsS7nP6pMY7IYPUVn+BLA3msvdSDMVsMj/ePT+ppNfm22oHccV0vw/gEXh2OTHzTyM5P0OP6Ve0TJrmqWOqt4wWGea6Gw+TBRRWJZ4aQKoLN6Dt9a6awgcAFto9hz+tKKYq0lsyyZpSB2+lILyVM5Y4q4sQxVO7j4NW7rU5I8snaxh3+o20sk6PKiGMgNuIAGa4DxK8YvzJazJiZNsvzY5HQ89eP5V1R8PWs2s3l3qMLTK23Yu8gdOelVNZtLOLUtJNrawwIJzlUUDPyk80ly7s3XtE7Rsl9/+Rz+ma4kYtopZkjigDyfISSxBO1SMcf/AK69F0O/W9sYZojgSKDiqMtzpt1bTx3CwhVIif8Ad8gnoOlamj6fFp9pFbwj5YxgE05u70VjKjHki05XNKKLd1qf7NkdKktl4q2AKpRMZ1GmZMtvjtVGeLGa3rhRis24XOamUTWlUb3MSaLOeKz54Mdq2J1OflIH1Gapzq4H3Vce3BrJo7IyMg5Q1v8Ah3XpdPcIx3Qnsf4ax5Qr529R1B4Iqtkq1RKN1ZlzhGpHlkjT+L/ho+L9IhvtMiB1O0BKhRzKh6rn9R/9evD9Nu8w+VKCCuVII5Br37w9rX2YiG4JMJPB/uf/AFqxfiZ8O7bUoZ9c0E7NTI3yW6fduPUgdmI/P8c1jTqulL2dTbozhjfDS5baHh5Z7SbeoJjJwwq4VWdBJEcg1DalbmFkbrnvUCmXT5WOMoeor06dTl0Yq1Hm96Jo6Rp0mo6tb2cS7mkcDHtXY+O/Al1oR+2WSmWxIBbHWM+/tXT/AAr0GztYYdXvyy3Fwm+JGX7qHofxHP416lOba4VkkKSQyDB6YrixGNnGr+71S/E5H7tlJP7j5VhnwOtWFnBHWvTvGnwwWVnvfDrgMfmaA9D9K8pv7K706dob2CSGQdmGK9GjiYVVpv2Jsmrot71I61CxBPBqn5pCnmn27Eg5re4rE5XIqvJGDVtRxTHWmSZskeKSGVoXBU4q66ZFVJY8GlYaZ0+j6nuA55712ulXodNpOQa8ktpjBICOldbo2o4wc8VSdyJRN7XbNXyyjrXFXtvhiMV3Ml0ssPNczqMYLtimQjlLiIqc1HDIUatS6hyDWVMhRqlqxZ6F8MfFr+GtdjlkdvsE+I7lBz8vZseo6/TI719PRSJNEksTh43UMrKcgg9CK+J7OXDCvon4GeJW1DSpdGumzNZjfCSeWjJ6f8BP6EelDV9TCrHqepUUUVBgFFFFABRRRQAUUUUAFFFFABRRRQAUHoaKbIcKamcuWLYHFeKAyXfP3WGRXNS/un39Aev1rvfEFkbyzOwfvEO5a891V/Lt3DDB6EelYYeuqkfNFqDbSRzWsyk3LYPyudw/rWdIMS7h0cZ/HvTriQyKWPVDkfSmucxA/wBw5/A1zyd2fU0afJBIjuzi9hkP/LRNp+oq1avtkOehGKqX3NtE46xv+hqaM4YGpNXscT4jJy6+jmu90JWTQ9Pgt+MQqzt6ZGcfrXB+Jhi5kX3zXo2iKqaNY7e8KE/UqKt7GUPjZ0GkQsu0B8fRa6q1jwoy7sfc4/lXL6a2CK6ezkBUU4s566NGMfLVK871cEihetULqQHNVLY56afMcje+I7SC9u7W4Y+ZGwVERcs3GawdX1GeSWzkFhcxqkwKGRdu4kEAc49a7GK1jtdRub6JVE0yqCdvPFc/4pkkuNOnkYlnhZZR/wABIP8AKoTS6HVyTlL4rLy/pmXFa60999r/ALLmeIzJK0aSLg7Rx39ea67wje3F5bXD3cbxyLOy7H6qPSqNrrcVtPJDKxULF5wJPDD2/MVq6PeQXdv50CGMvh2U9RkZGfwxVSbaV0Y04Rg5KLvc6S3birKmsyGUcVbSYetUmZTg7k1wflrLnkIJHluQO4x/jVqaYHvVWR+KUmVTi0Zs7OT8sZH+8QKqus2Pvxj/AICT/Wr8vJqu4rJnZEyrqKRjkhCw6MpKkfzrMlkePi4QqP746fj6VuzCqcyBgc0mbwlYzPMKnrxXW+EtYCyJb3DAqPuE/wAq426t2gO6AZTumf5UlpcYYPGSCD+INZ1aSqKzHVpKrBo6TxZ8LNK1eaW+0Wb+z72QlmUDMTsfUdvqPyNeM6rp81rfXWnagirdW7FHwcg+49iOa+itI1CHULNX5jYYDhDgg15j8XfCz2V+fEOnmWe2mwLoHBMZAADcdjiscPW97kmzzKLnSlyT2IPhN41t9KaXQ/EM6JZdbaWb7qHPKk9h3H4+1e42dlYyWwniMUscg3K0bfKR7Yr5LubdbtXZeuMiu9+C3i250zURoF2Xa2uCzQEZOxwCSPocfn9TVV8MnepFaixFKSu4NnvawxIcRnAPas7V9HtNRXbcW0M4I6OoNNaXzEaQb1fOR8pAp0NyJSqyEhv51w2bXmcnLKD5+nU5uD4deH5bjcbBVIOcBzj8q8R8V262PifUbeNdiJMwVfbtX0/Z+XFdOifN+73Z9eleF/GjRzaa4mpRqRFcja3swr0MBVlGpy1G9V1KUue7Wxx8C71GKJIqgspgCBWkQHXIr3EZszGSoJU4q/KmKquKAMyVcVNp94YZNpPy0+ZKpSJzU7Fqz0OytLvegw1OueVzXI21zLDja3HvWrBeTygDZmrUrmbhYnlUEGsm9iwc4rYVXIy64qpeR5U02SYsbbWrsPA2vSaDr9lqEZO2JwJFH8SHhh+X61x0o2uat2MuCBUoGrn2xDKk0SSxMHjdQysOhB6Gn1wvwa1f+0/BVvE77prJjbtnrt6r+GCB+Fd1UPQ42rOwUUUUCCiiigAooooAKKKKACiiigAqCZsAmpmOBVd+a4MdU5Y8qLgtSGQ5QMPrXn/xG0uSOH7dbD9yf9aB2967ssySGM8qelNMST20lvOqujAqVboQa8elWcJXR1037OSkfPIkzlT3BFOhYNHz3GDWp4z8Py6DqZChjZyEmJz2/wBk+4rCifaXH416UZKSuj6OLU480SwRvtZF7lf1FIj7rdWHpmi2bJYH1pln/qmX+6xFUM5XxMM3ZP8AeGa9A8PP5mgaew7RBfy4/pXB+JEIeM/UV2XgeQTeG4lHWJ2Q/nn+tU/hMo6TZ1Fk+MVs2d4p4VgcelcxFIrSFScqvG0dWP8AhWjFcYHQr7GjYJx5nY6I3fHWoJJ896yPtXHWo5LrA60XuQqaRBr+pXlpdWws4BOJgybS2AG4IJ/WsnUo9RGn3E95c28ShCWjRSwPHTORWo8nmkbgCAcjPasLWJW1K6TT4MmJDvmI9PSmpWB0VJ6t/wBehU0vS11vT/tU1+wYr5LKYw2zB6Dniun8OrLYLdC4mMxkk3K5GCRgCs6LSbnSRJewRsbCQgSoBnacfeH51N5vAeNtyHoRSVVVNE72CFCnFtx6nVR3gPerSXWR1rkY7ph3q5Den1pXKlSOjM+aDJkVjpdZ71MlxnvRcn2di8xzUTUwS5oL8EgZ9qAtYilWqcq4NW2lA++pUep6VWnkjX70iD6kUmXHUpzrkVj3UBEm+M7XH5H61sPJGT8siH6MKqXCgjIpI2V0T+GdVW2vQJdyoflkUdR7ivVLa0s7i2Ky4mikXDIwBDAj9a8UmjO4Oh2yL0P9K7TwNrUkj/Zi+JF4CN29v8K5MRSt+8ijkxtB1I88HZo8t8faFF4X8YXFlaqy2UyCa3BOcKeq59iD+GK56PzYTDd2kjQ3MLbkkXgqRX0D8R/B8ni/SlaJVh1K1Ba3kJ4bPVD7HA+nFeBRJJD51tcxtFcRMUkRhgqR1FdVGp7SF3uZYeoqkeSW6PYPhd8R3165Gka8I1vQuYpV4EuOuR2OOfz6Yrvb22M8j+SMlRuHqfavleCSaynt760YpcW8gkRh2IORX1p4XvIdV0Oz1CAALcRLJjOSMjoa56+FvJSpnJiF9XlzLqVYJRG8TtwzqVNZ3izw7Hr2izW1yMM4yh7qR0Na+qGO2bzI0DEHJHpSw3aXcJ+YeYB0PBrKerunqjnTcEnFaHyhqdjcaPqU1ndKVlibH1HrVq0usgA17l8SvBEPiGxF3aKEv1X5T/e9jXz/AHVvcWFy8F1G0UyHBVhivZwuJVaNnuty2lJXRruA4yKpzJg1FBcsBg1OzhlrsJtYqOMiqkqVfdearzLxSAong102kxq6rgVzMow1dB4en+6D2ojuE9jon04mLdjisO+t9hINd9ZqtxYkdwK5fV4cO3FWZJnC3se1jUVs2160dSjwTWYnD1L3KPafgFq/2bxFPpzt+7vYsqP9tMkfpur36vkPwfqR0rXNOvlJAgmR2x3XPI/EZr68BBAIOQehpSOaqrO4UUUVJkFFFFABRRRQAUUUUAFFFFADJTxVYHcallPNVd+2Xn7rV4GMqc1TyNoLQZcKSxZPvLyKRSJFDD/9RqS4OwBwM46/SoXjwQ8TYV64WuqNo6op6xp0GsWM1ldplXHXuD2I968O8QaLdaHf+TcrmNs+XKBw4H9favf3jKAOpy1ZWu2NnrFibe7h3fTqD6g9jW1Ku6e524TEOk7bo8EhfbKfcU63bbPMD3+atzxL4Sv9HnM0Ctc2Q/5aKvzL/vD+tc2ZB52c9Vr0YTjNXiz2YzjNXiZ/iAB4iR/C2atfDu8kW+u9OUgGcCRCe23rj3wf0qnfsJVlT2rCjvJdK1G11CD78LhiPUdx+IyK3irqxzzlyvmR7Ksa24KoMDv71E8vNSSTR3FvHPAwaOVQ6kdwRmsu/vIrNA8xJY8Kg6sag3WxoI7MeKZdXVvaLm6mVPbPJ/Csy3i1TUsEP9khPZOWx9a19O8L20TeZLmSU9Xc5NAm7GW9zeaqyQadG8ELHBmcYJ+grotH0eLT4Z4YwS2z5nPJZj1Na1vaQxBdiAbelXrWHzZ1RRy5ANKUlFOT2RlKdjT2R2fhlFmVTuTJDe9eTXdnfW88t9p67o5G3PA3Qg9MehxXp/jCXfFHYxtgyEJx6Hr+mapCBNm3aNuMV4mTRlN1MRL7T/4c58M7LmfU4C0v4Lo7BmK4HWJ+D+HrVglkNbmqeGrO9GSuHHRhwR+NYk+n6lp6kDF3EOzcN+de4dsZpj47kjrVqK696xjewbts6yWz+kq4H59KnQhhujdWHqDmgrQ3Y7n3qyk4PeufV2Wp4rgg0hOJvBwaa6qew/KqMFxnHNW1fNBm4leaFG6op/Cs+a0jySgKH1U4rYYZqrKtF2VHTYwZlmiPIEq/k3+FNt7hluFltn2XEZyAeCf8+taM6cGs6aJGPzjOOh6EU9zVa7nrHh7X/t2mxyBsODtkU9Vb0rzn4reEp7u7k17RojJJt/0qGMZLAfxgdz61P4YuprG+BR1dJMKwfj6Z9a9RtLoLFn7Nhj1ArzXGdGrdPT9Dya8Pq0+amtz5Wsys0JHua6PwT4z1DwjqccUk0kujM+JYTz5YP8S+nrjv9ea6z4seFURTr2iafNHIrZu4okJDA/8ALTA6Ed/z9a8y3JcwMRzmvSTjKN90zeDjiYWaPqy2Avo4p45I3gbDKynORTrm1gj+aJAh77eK+YvC3jPVvBd4Daubiwc/PayMdp/3T/Ca948K+Kj4t0iPUbK3aGMOUdJTnaw7ZHsQfxrgnQlR96Kujza1GcHZuyNtZzDIqyHMecg1znifwjpniKby7qMCcjKSLwwFb0sVxImWEeM8bc1NYLmVHI+YfKSaxcWp80HYUJ2i29zyTUPhHFZwST/b5RGvbaK8snURXkkcLs0StgE9TX1Rr7tNZTQ8YZSAR3OK+V5lMd1KjcMrkH869XL606rkpyvaxerjdl3y8pmq00daEOGiFRyp1r1jK5hXCYzU+kTeXcAetPuo+aqx/u5lb0NTsyt0en+H7kldpPBFV9aj/eNiqOgznCkVo6k28En0qzDqcVqkfWsJxh66TU1yGrnZ+GpMtGhYNwK+vPCN7/aPhfSronLSW0ZY/wC1tAP6g18fWDcivqP4O3Bn8AWCnkxNJH/4+SP0NKWxjWWh2tFFFQc4UUUUAFFFFABRRRQAUjHApaZIazqy5YtjRAzZYj0qncgncvpyKnmbY4ft0qOfDEEHpXzNWXM2dMNGmQxNNJHjr2zTwhjynVP5VEjtBJk8o3pVnzMndg7azjpvuaSunpsQGSQAr1ApbZSCWccVJLGMbl6eoqurmOTDcik1ZjXvLQfd48okRjNcnqvhDRNVLtNaLFM3/LSE7Dn8OD+IrsHmRk+YYqo4iYHkfjxTcpRfNFmlKbj5Hkuo/Cmbez6ZqOV/uzp/7MP8K4fxF4A1+1Bg+wvc7s7XtvnB/qPxAr6L8042r90ehoiZWnAPQetawx9SPmdXtp21PnnwRqV1p6PoWuQTW1xCC0AmQozDqV5/MVu6Hafb5nv7r5ixwgPRV9BXpvxB0Cz8QaFPazbVcDfDN3ikHRgf5+1cPoVu1rpVrC5y6xgMfU45NehRxCrJu1mjqwtRzia1uoQAKABWhCOlUoBmtGEdK2RtMmQVr6FDmV5m6Rjj61lqK2rhxp+hknh2GT6815mb1/Z0OSO8tP6/L5nHXenKupgSM17rU0x5SLgfU/8A1sfnVvYabplsYbVQ332y7H3PNXPL9q78Jh1h6MaS6L/hx81tCoVqJ4wRyM1edKruuDW7RSkZl1p1vOCJIlP4Vi3Hhi0LFok2Me6nH8q6lhTCKk1U2jip9GvYOYJ2YDs43f8A16gBuYji6tz/AL0fP6V3RQGoZbZHGCooNFU7nMWhSYZifOOo6EfhWlCCMZq4NPiWTeqgN64pWhx0pDcrkXaoZVqyU4wRkVXmhcA+W+32IyKATM+ZetZ864NaE63K9RG/0JBqjPKB/rEZPcjj8xTRqriWr7WFeo+GNUjudL/f7TLFwc968pXG7IIIrpvCl4sN8iStiKT5WPp6H865sTTco3W6OfFUlVgegpcuTkhQp7Yrw74xaPDpeqQ6lp9ukNtc5SZYxhfM6g47ZGfyr22W0OzKzqAwyDjFZ+o6Jp+p6XcWGpypNFOuGA6g9iPQg1yUJThJN7dTzac4wfNE+Yr3bcQAivVvgBfvLp+q6ZOSY7ZllQf72QR+n615j4k0qXw74hu9JnfzDAw2uONykBlP5EV1vwX1u10jxdNb3b+WuoRCKN/9sHIH4816GIgp0mjprvnhzRPfLbLPs2kKe39akmkWLhOp5z705j5aMVwFPGepaq0ybhGT/eNefTcVBxR5b1qJ9xssLXDkgcAZ5r5o8ZWjWHivUoGGP3pYfQ819Sw7YbfJIAPWvGPjN4eeZ11q0QkKNswA7djW2X1Y0q1n1NotyTXY85tJuMGrLYYVjwyYIxWjDKCOTX0aZDRHcx5BrMmXGa2JSCKy7jgmhgjoNAn2xjJ7Vs3M4dK5XRZcrj04re/5Z5qkZtamTqAyGrmrofPXS3x+Vq5u6++aUhonseor6Z+BhJ8EMD2upAPyWvmax619QfBSExeA7dz0lmkcf99bf/ZaT2Mqux3dFFFQcwUUUUAFFFFABRRRQAVDLyCKlbpVd2+ciuHGztGxcUV2IZSjfeFQQnEpRuhqafG4EjpVRyVlz3HNfPSep1wV0PYfM8bdexpIZwBsdTkU+ZlkCvGfmqFshtydf50n5FJXWpYRyiZIKg9j0qOY4xlcr2IprXcbxFWP1BqvDMzAqD9BSc+g1B7tFhWTHTP1qO6ESwsV4NJJIYlJkTnHFIlv50LFmIyOTU88muVFKKXvMbHtjiJI61RKu5d+QewxTwZWl8piNq85HerU7pFFx1xzWO6N1eL7tnJeKL2aO2htgObklSQfuqOv88fjWLGuMAdBVnWJ/teqMQcpANi/X+L+g/Co4l5r28HT9nSXd6npUlyxLNuvStGIdKpRvHGBvYD8atwM0pyFKxjuRgmuxCkaemW/n3SA/dHzGtDWoluIkGcqsgBH6/0qKB10zSpLmThmHy5/SqOjTSTWdx5+d5lEnPoRXzlWTxWPjNfBBpfP/h/0OCV5S5+i0LsUdTFOKWEcVIRX1SREnqVHWqsi9avyLVOQc1LRrBlVhUZGKmYVGwrM3TI6Q9afTT0pFoaRzUbCpTTDQMhZaideKsNUbikUjOuErNnXqK2Zl4rLuBzQaRZkSwbW3RHYfTsalt7maFhugZsd0OallHNMjbawp3NdHuekaLqk+oadEUtZWwuCHGMEVKTeK+VtoY/cuDWP4Nu323ECnll3KP5/0rpt0aKNy9q8er+7m4pHj1YKE2kvxf8AwDwr4z6HfR6wNckKS286rHIYwf3TKMDPsR39fwrzOecrJG8bEOpypB5Br60u47a4ieGaGOWKQYaN1DBh7is2x8D+HLa4ju4dDtEuFO4MylgD6hScfpXZh8Y2uWau/IHUVOPkbmlyzPounSXaEXTwRs6ns5UFuPY0styDKEXkrx+JqS7cxKXdh5rcDNV7YRRhZDlgDyx7n61nOmoK21zhopzk6jWi2NG72xxjeenFZeopDc2rRSgSI6lWU9CKv/bLWQhZyxB6E1ILezY7lU4HNYVKPLqmjSnUUfiTufPnjXwHd6Q73enq0tkfm6crXFQPIWwRjFe3/GnXXtdMisLZtnnnBx/dFeMWyZ5Ne9gZzqUrzLk+tiUElOap3Azmrz4AqrKBg13GZBp04gnIY4Bro1uQYsA1gWdssrsWGRV42hjHyOyj0pxuKVmxbx8qawbjl617jITk5PrWTJy9EiUWbEdK+t/h7Z/YPBOjQEYP2dZCPQv8x/8AQq+VNFs5Ly8trWEZlnkWNB7k4H86+yIIlggjiT7kahR9AMVMtjCq+hJRRRUmAUUUUAFFFFABRRRQAjVTuAchk6irb9KpyPtfGeteTmDWiNaZHIyuMdyORVZs4z/EnX6VOQBckD0pkqmOUE9OleMzpjpoV4pBFMNw+RuhpXysxHRTyKfNB8uVOR1FUyxiuEaUkp05qJXiaxSlqi0yRMcsuR3x1FMtXjWeToMHii9ZAnmxNgrUEsWYEuE7jJpyfM9FqhpXWvUlvJDdb1jHSqL3zovlbWD9MVZ02ULGW6k1VnPm3AcD5Qax1l71zWEVFuLWiFEbQwGTdmQ8kH0rlNV8RvMz29oph2ko0spAII4O0f1rqNSuFEJL4UAcknGBXAy2sEtzNNt/1js/5nNdmCowqSbeyOrDx5tZoRJ4Y1Cq2T7DOaniE87YUGGPux+8f8KEtISMeWMVbtoZI+FcOvo3UfjXsaHa2lsW7O3jiHyrz3J5J/GtjTrf7RcKh+6OW+lULZHYgbRuPAAOa2L6QaXpxjT5rmXrjrXBmGL9hT5Iazlojiqzey3ZR1m4GoaittGf3EPLe9WLYbJjgcOu0/hyKo2NuYY/nOZWOWPvWhCvStMNgVRw/slvv89yGlGNkXojU2MioYhU46V6iOWTIpBwapzDk1ekNU5amRpTKbiojVhxUDVmzpTI2ptPamGkaIaelNNPNMNIYw0xu9SGmNQUirKOKzrla05BVK4XikaRMuRaqv8AKa0JBiqM45NI1RueErsW+r2zNypbYQfQ8f1r0026OctGP++q8bsXKyKQcEHINepWtw93bRy/MoZQeTgdKwrOEbOSPLzClNyUouxpCOKL7vlofYZNQXEwUEpl29azzyxBlx9Bmrlta5QvuZ/94/4VCxkUuWmrHA8NFe9UlcoJaS3M43sckgFz2HtWz9hUIsSjEQqtb703kNuAAP61dvLgw8AVhUjHlUm9wlVnKfs47IjtYUw0akZHGMUkvmrlSI1/2s1Vil2T+cpIJ+8D2pbmXzn/ANmsZtNJoag1NpniHxpZv+EgtYzyFiz+tcVb9K9G+NWnOsljfBTtAMbe3cV5rC1fQ5e06EbFz3JJjVWU8VNK2TVSU12MlGnoqbz+NbtzCqwdKyvDy/KCe9a+puEhxmrWxlLc5a+bGRWag3PVq9fLGm2seTmk9WNbHpPwO0U6j4vjunTMFghmY9tx4UfmSf8AgNfR9cD8F9C/sjwhHcyptub9vPbPXZ0Qflz/AMCrvqiT1OSo7sKKKKRAUUUUAFFFFABRRRQBFKwUc1n3RLSKV6LVu9GUwOtVYZA6Mp4YV4OYO87HTSVlzEU7FLhH7MKS4nDpgdac3zKFP3lPFMKxffxivOndrmRuraXBWZMFvuGmXJRkOFDjvVvb+6yOmKoSpuQvE4Ungqe9J3SHBpu5WnSNkXymJDH7p7VO0TxwgM+2M/w1VjbypwZKkurzzWQfwg1z861Z0OMnZLYR4ikR8vhT1FERh+yNnBJqy86GEKBxiuR8Q6kliFjhkTz5Dnax4C+pq1zSkoQ6l0qbquxQ1+RpdQCCVzAqglM8bsnn8sVUjGaiSTzWLbw7HkkGrcKV7lGn7OCiemo8isSxJ0rRtoCyl2KxxL1dzhR+NVYkyK1dM05J5PtFzkxR9Wc5/AelRiq3sKbm2kl/Wi/4JhVnyq5paY1rBZG7AYgZCyOMbvcD0rLh8y+uDdTZ25/dg/zp1/cHVbryoxi0jODj+L2/x/L1rQhjwBXBleEnUm8XX1b2v0Xc5F7vvPdkPl4qaJcGp/LpypivfSJdS6HR1JmoxxSE1RluDtVZzUrnNQP1qWawRC9QN1qd6gbrUM3RG1MNPamGpNUIelMNOLLuxuG70zQaQxlMepDUZIIyDmgaK02QPlAP44qpK27IwQR2NXZKpXKkjK8MOlI0RQl61TmFWpJVLlG+V/7pqGQUjZEVvw4r0Dw3OZdLEefmTK81wCcPXXeE5sPJH/eGf8/nXLjY3pX7GGJV4HWQRMRkqP6VZfdDDksAveqRuSgG8nHTAoYPOyh8qhPQ+lebFpbHkuLbvLYdbzk/dH3uKkvXkZhuIz2FLEI1k6gBegqrcys1wpTkKea1q1FyJXJpxvUcrBG580+YO351h+IvFmneH0Y3UwMxHywpy3/1q6BtPur20uXgby5DEwhJ/v4OD9M4r5XvGne7mN40jXG4h/M+9u75rqwWXut79TSP5lupG9ludJ4y8cX/AIija32LFaZyFxk/nXLQlgPmp8SgnmpWXHavoKVKNKPLBWRm5XImOaryHLACrD1JYWpluAxHyjmrDbU2dMXyoV+lRarc5BGamlYRJisS8kMjmrMd2U2y8ldt8NPDDeJPEUFs6n7HF+9uW/2B2+p6fr2rmdKsJ768htrWJpZ5WCIijkk19RfDvwrH4V0JYG2tfTYe5kHduyj2H+J71LdiKk+VWOnjRY0VEUKijAAGABTqKKg5QooooAKKKKACiiigAooopAV7td0Zx1rJL5bn5XFbE33c1kXCb3cqOleBmGkzroPSzJIz5mVY4aoX5Yo3DH9ajRmbkH5h2qCeV5GBAOQetedzcp0xpu5J9plRSgUn3otV3yZkPFSyNGtt8x+c1RBdVOCeehrOS6p3LjqmrWJr5kzhQCQaqgIyOJAV9MVas4g2CxySepo1V44oW28tioa0bZcXZqCOK1jW7yK9ezsjGyIo3SNyQT2x9MVkxxlmLzMZZG5Zm5JqW5CG+uWiACtITx3Pc06Ncmvcw9KNOK5VrY9SEElcRbWN/wCAA9iKv2sRUck/QnNEKVq6ZYvdzbR8qDlm9BW1SpGlFzm7JEzmoq72JdKsGupMn5Yl+839Kl1S7891sbL5IU+8RTtW1BUVdP03AJ6kdh6n/PNRWkCxLgck8knqT615FCnPMqir1Vamtl382cd3J88vkWLK3SKNUjGFFaKLgVDAuKtKOgr6KKMKkhVXNPIwKcq4FI/SqsY3K7U0mnPUZNSzWKEaoHqZzVdzUs1iiNjUJqRqiaoNkMNMp5plI0Q10VxhwGHvUZR48mNiw/usf61N2pKBkMcqyg4yGXhlPUVXmPlHePukgMPr3qS6txIwkRzHKOA6+nofWqF4l75LKDDKODwCrHB/KkXGN3YtPVWU1KkqzRB0OQf0qCY0ikUbqNZRhwD6e1UCzQMEkO6MnCse3sa0JTVWVFkQo4yppJ2NVruRnhq3/DMuy+iz0PFczEzK5ikOWXofUVuaI2LqHH94D9aisr05LyFNXi0zvd4Em5uBmpJ5d5Ta1QSRfuwT2otYPMViDjJxXhJtxseU1G3MTuiJHkn5qsadZCaUjP7scufX2qvcIIwPmya6GxgFvbIn8WMt9a7cDhlXq+9tE5q9Vwho9WTqAqgKMAcACvDPjP4BnS8n8QaREZIJTvuoUXmNu7gdwep9Dz06e6UV9OtDz4TcHdHxXGTnFXI0ZhX0b4i+F3h3WHeaKB7C5Y5L2xwpPup4/LFcdefBm+iz/Z+r28o7CaJk/luqrnSq0WeVR2iuckVdRVgTAxXcj4UeJUOFk09h6iZv/iasW/wg1yZh9r1CwiX/AGC7n8sD+dNWB1F3PMbqQscCm6XpV3qt6lrYW8lxcOflRBk/X2HvXuWk/BzS4GDanf3N4R/DGoiU/Xqf1Fd/omh6ZocBh0myitkP3ioyzfVjyfxNDkjN1ktjlPhv8PrfwugvL0pcaqy43AfLCD1C+/qf8nvaKKi9zBtt3YUUUUCCiiigAooooAKKKKACiiikwILjPltj0qhGMqRWnKMqax7gSI58vkeleRmUPtHTR1VimHJvBGo5PWrOoKkUHA5PeqTb4rlZXGARilnmNw4jHPc14PPZNHdyNyTWwkW55fnAGBUl+UCIijLUxxsG8D2otl8x97cDtmiF72HKy97sV7i4+xwtI/CKpLH0ArktZ1030DR2LkBxjzcYwPbPeuj8T3CJaShemwg++Rj+tcJGoChR0FdmDowqNzlrZ/I7sNT5o8z3KMdjcr9y5lH1Oav28d/Hg71k/wB4f4VYiStG1iZ3VUBLE4AHevXvHdo65VJ9ZX9Uv8h2jie8uVtzbskh5J/hA9TW5qN2LaIafp+GfHzMf1JpbqX+xrRbeBRJezcNjt7fQVky6a8xEq3DpcgffB4P4V5Lh/aNS7/hR/F/5HFzKrK8tF/WpdsrVYVwMlicsx6sfWtGKOsGyudSS5+zzJCz9Ru+UsPYjg1uW73p+9bRj/tp/wDWr24R00RnW912uXo0qxGuKrIt0RyYU/At/hUwW4Uffib22kf1rZI4pyv1LHSon5qFroxti5jMYPRwcr+fapSQRkHIoYkiGSoj0qWSoGqGbxGMahepWPFRNUM2iRt0qFqleomqTRDG6U004000jRCUUvakNAxjVA9Tv3qB6RSM65RoJTNCCyt/rEHf3HvUPnJMm6Ngw/lV6TvWZd2wZ/MjYxy92Xv9R3pXNVqMkqButMlnliOJ0yv99OR+I7UJKkgyjBh7GlYvbcrXiEgOn305Hv6itXQ5A81u68gspH51Rcc1a8NADVIoM9JlIHsTSl8LQVPhv/X9f5noklyrwsq/eIpsCumwI2Cw5qe4twiEgAZpk58vY1fPJNRuzyFJP3Y9SaGJpL+BHOTuyfoK6iue0QebqRkP8Mefzroa+gyiFqUp93+R5+MfvKPZBRRRXrHIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUGiikwEPSsy/QA5HBrUqvdIGXpmuXF0+emzSlLlkYNx84VScjrTlMccRAUK3f3qS6T5wqqM1E1q7xn5vmr5qUXdto9FNWV2NUeb8zfd7CqV5fR2cbiVguBnJPGKp6pq40xVW4GGYkLgZzXJ6nevqTDzVxGDkKepPqaqlSlX0tZdzso4dyd5bDtR1F7+TjIhByAere5qCNaqCB4juhbA7g9KvW6zfxKhHsTXrU6UaceWOx6NklZFmGOum023XTrB9QuF/eY/dLj9ap6TZRiI3t8dlpHzz/ABH0rRuL46lYW8m3akjFlH+yOBXnYuu69RYWl1dpPt1t62OGtNyfItuv+Rm20cs0rXFyczP2/uj0rSijpIY6txpXsUqUacVCCskZTlYjms47mPbICCOVYcFT6ipbGSQN5FzgyqOHHAcev1qwq8UTwedHgHa68o3oa6EjmlPSxZAwKRqjtpTLArMMP0YehHWlY1RlbUCeMGokRIwRGNoJzgdKUmm7qm5aQP0qs5qV2qBzUNm0EMY1GxpzGoyahm6GN1qI09u9MNJloYetIaU02kWMm37d0f3l5x6+1LHIsiBkOQadVWaBw5ltmCOfvKR8rfWgomeoHqH7WysEuozEx4BzlT+NSSGk0NIgkqpL3qzIaqympNUU5jVRoImbcVAY914P6VZmPWoTSNUQtAOiySj6N/jWj4dsSdbtJPPkLBu+OwJqmOtauhyCHU7Z2OBuIz+BqKzfs5PyZM3aLsvwPRpVPkAs2ap3JEqIF5Oc1NczqYQM8etFmoeEmvBvzXR4iXJaTLfhcZ+0MRyMD+db1ZGgAJ9pTvuDfpWvX0+WK2Gj8/zODFO9VsKKKK7znCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmSruU0+g1LV1YadjEvGMbn5CfcVmXOqJawPLcZRV5JPQV0l1H8jNXnfirzrh/LKlYAckf3j714OIwM3U02PUwnLVfKzE1bUTqlyJNhWJM7M9Tnv+lVlXNOEeD0qaOPNdMKahFRjse2koqyEjjzxjrW3o2mrKhmuWKW0fVu7ewpdH0zz/30/wAlqn3mPG72FOv7k6g4hhGyxj4CjgN/9b+dcdevOpP6vQ36vt/wTnqVHJ8kRt9cHU3GwbLKL/Vxjo2O5q/bJts7NP7sI/XJqvHGAu0Dtir0K/Kg/uqF/IVvSwsaMoRgtFf79PxMZWVkieFelW4044qGIYq3EOK9FI5ZscFwKXpTjUZqzDcgdjBKW/5ZORu/2T0z9DUhNNnXzInQ/wAQxTM0maJAxqNmpXOKiJqWaJCs2ajanUxjUmiGGo2p5qNqk0QxqjantUZpM0iNNFBpDSLEcsB8oBPucVWluGj5lhcL/eX5gP61ZJqNjSGis7Q3cLBWWSNuDg1TtZGAeCRsvEcZ9R2P5VNc20bsZFzHL/fTg/j6/jWTeyT20qyyAFxxvUYWQeh9DQaRjfY0JDVWQ05Z0njEkZyppjc1LLRVl5NQHrViQdarnrSNEPQVr6Fpp1G+QMSsMJDsR1J7CslK6zwXIgFwuRuDgn6YH/1658VUcKTaMa7ag2jpo7COMbmyQOxqCCVlTgHb04q7eXK/ZmwecVFp8f8AogY9TzXi2S92J5Sk3HmmXPD7l55yeOBgVuVzukPt1faOjKR/Wuir6XKZXw6XZs8/Fq1S/cKKKK9I5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooACMgg1g61pizxsQOa3qbIgYYNTJXRpTqOnK6PLrvTWic/LVm00tIIxcai3lQjkIThm/wABXaXdukWXSMPJ2J6CuU1K2lluDLcsXIPA7LXj4qlXm+Sn7q6vr8v8z2aWJdVW2Kt7dyaiVQJ5VmvCpjG4f4UsaY4A4FOVMVKi1eHw8KEOSCOhJRVkOiFW4x0qKNasxpjmulIxmyeJeatJxUEfApxcCtVocstSYmo2ao9+aQtRcSjYVmqNjQxqMmpNEhGNNxmlJ4opGiENRtTjTDSZSGnpUTVI1RNUloY1MPWnNTDUs1QhpppaQ9KChjGomNPc1AxpFJDHNV5cFSCAQeMGpWqCWpNEY09s9o5ltM7OrR/4VYt7hJ03Kee4qwx5rMvYWiYz24ww5ZfWhPozZrn16/n/AMHz+8sSmq2eaVJ1niDL3php2sCdyVDgZHNdxoOhvbWSyBsXcnzSf0H4Vx2lKH1C2VunmD+dep2DqifN0xXmY+d2qfRnFjKkoJcpmvDNuVZiMZ6CrsAY2wxxjgiorqTdcAjoM1YhkX7P2zXnJJLQ4pybSDRxt1JWbvkD64rpa5VGPlM6cMrZBrpbWYXFvHKP4hn8a93Jqq5HS67nFjIu6l8iWiiivaOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCKVARWRf2gYE4rbYZFQyJuHSolG5tSqOLucZPblGPHFRotdJeWm4HismW3KHpXNKFj1addTRFGtWBwKiUEdak60IJajtx7UmTSUZpk2FzQTTaWgBGNMNPNMNIpCE03NB5NNNSWkDGmE0pppoKSEaomNPNRsaRSGNTDSsajY81Jqhc0hNNLVCzbZiCeGGR+FIoVzUDGnSNUJakWkDGq8pqZm4qrIcmkWiI1BIamY9aqynmkWjMkP2W7x0ik5X2b0q115ptzEs8LI3fofQ1Dp0jvILd1JnB27R1P0q1qrFz/AJ/v/wA/0fyNzQ9Nmv72Nom2LAwkY+voP0rvEdxGFaN93TpWX4Ps7jThMt9GsbSNuT5gcjArqp5Y1iJGM4rwsXL2tRu+iPJxFa87WujLto2eU7vSlktpEbCN8p9e1TWThCzN3pl1P8jkcVyy5eVGScud2Jo1VbfYvPqa0vD7k2rxn+BuPoapWag23virGgnFxcDtxXoZbJxxEfO5z1tYSXY2aKKK+pPNCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCKKKAIpIwwqhc22e1alNZQeoqXG5pCo4nOS25U9KrldtdFPbgjgVmXFv14rGULHbTrqRnE0nWnyxlTUdQdK12HClJpmaAaQ7DicVGxpSaYaTHFCGmk0ppppFoQmm5pWNMNIoRjUTGnsahc0mXFDXNQsacxqMmpNUgzUNynmKMEqwOVI7GpCaikPFBSKMtzJCf36fL/fXp+PpUm4EZB4p0nOQRkVnKxtp/KJ/dPymex9KW5pbsW5Hqszc0SPULNUlpCyPxVZzmnu1MApooTFbvg7TEu9V+0uvMHyqfc//AFv51igYGTXf+CLcQaZFIww0mZD+PT9MVy4yfLTt3OfE1HTpuxtahbq6IrcEdCKprbF1zI52irOoXG5wF6Cq8ruLcBOp714snHmbPMp8yikQnesW9RkU3Y8qbnGE61fjj22oB6U2yAYSxHoKjluy/aaNklq+IiM8Gr2hJzcSdiQtY8NvJtIVzgGtXQG8tpbcnJ++P616OWSX1iPN5nPiIrklZmzRRRX1R5YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRyRBx0qSigadjNns8jpWdcWhByBXRkZqKSFW7VnKCZvTruO5yckbL2pn1rop7JWzxWfNYkdKxdNo7oYiMjOxTTU8kLIeRUD8dahm6aYwnmmk4paQ0i0NNRsae1QuaRSQjGoHNOdqgY1LNkhCaQmkJppNIuwMapySeU+HPyMeD6H0qw7VXm2spVgCD2NK5SQ2Rqo3oMkR2/eHK/Wh4pEJ8qYhf7rDdioWFwP4om/Aij5mkUEcokjDjvTHPNVYZGS6kikXZu+ZRnirBBJpPuXbl0YnWnKKAKe2EjLHoKBNlrTtMl1W4EER2RjmST+6Pb3ruoI302BYdrGNQFU9eBTPCliLSzjEg/eN8z/AFP+cfhW5eSR+SykDOK8XE1fbPR6LY8qviHKfLa6MTeZTuwcD1q3j/RRkchqLWMyrvb7q9BUi4dZV/GsFDli11ZlOd3ZdCxIR9kBFU7Xf5zbeMikFwQm1ugqSwJd3fHygVnfmkrCUXCLuTRSpECvemWEu3WIMH7+V/SmRxGaRsGlSDyb+3bOW3gVtQlJVIS7NCajZrq0dPRRRX2Z5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEZqJowe1S0UDTsUpbZX7VQuNOByQK2yBSFM1DgmawrSicrLZOnQVUkjZeorsXhBHIqpPYo/aspUux1wxnc5F+Krua6afSs5xWbcaVIOgrKVNo7KeIg+piOaiY1oS6fKuflNVpLWQdjWbTOqNSL6lRjTGappIXHY1CY2HY1JqmiNjUD5NWCh9KY0Z9KRSZVYVDJVqRSKruhNItFC7tzMoKnEi8qajtp94KyDbIvDD0rRCVBcWKXBDfMkg6OvUU07F3UlZu3n/XQVVHXtXT+HdAS7iW5ul3ZG6ND0HoT61zmlaTqN1JsChrYH5pemR3GO5+leiWdz5SbQAO2PSuHG11G0IP1OHE1Jpcq3/r+tQE7W37t1O4cZ9arNLLNJgAhT1JqxNMbiVVUZNXLi2KW27ocV4/JKW2yOXmUbXWrJbWMR2v1qnFn7Q4HpVu1ybQVBDC/2onHGK3cZStZGEdOa4y8iVVyRzVmHZHZnbjkVPdW5khK45qGC0mKbdvFXHDVOb3ULnUo6sr6dJ1PuavQwma7jcjgHNWLTTlhFXkQL0Fepg8tlG0qnQwq143fKPooor3DiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEKg0xolNSUUDu0VZLRW7Cqz6ep/grToqXFMtVZIxJNKjPVf0qu+ixntXR0YHcCl7NGixM11OWbQUqF9AHauu2r6Ck2L6VPsolrGVF1OLk8PZqM+GjXceWvpS7F9KXsYl/X6nc4T/hGTmpYvC5f5c4z1OOldttX0FLR7GInj6r6mVZaZHaQrHGo2qMCpJLJH+9Gp/CtGisPqNLsYe2k3e5lR6eEfcoAqy9v5i7T0q5RVRwVJdBOtJu7KcVoETbUi2yqc96sUVrHD01siXUkxnlj0pwAApaK0UUtibhQaKKdhBRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Nissen fundoplication provides a 360&deg; \"wrap\" or collar around the esophagus. Mobilization of the fundus is generally accomplished by dividing the short gastric vessels to the spleen. A variant of this procedure, the Nissen Rosati fundoplication, does not divide the short gastric vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Toupet fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Toupet fundoplication is a partial fundoplication creating a collar of approximately 270&deg; around the esophagus posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34693=[""].join("\n");
var outline_f33_56_34693=null;
var title_f33_56_34694="Posterior approach to popliteal nerve block";
var content_f33_56_34694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Posterior approach to popliteal nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is placed in a prone position. The tendons of the biceps femoris (lateral) and the semitendinosus/semimembranosis (medial) muscles are identified. The needle is placed at the midpoint between these tendons approximately 7 cm above the popliteal crease. A nerve stimulator is turned on and if no stimulation is achieved the needle is walked laterally until either foot plantar flexion/inversion or foot dorsiflexion/eversion is observed; local anesthetic is then incrementally injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34694=[""].join("\n");
var outline_f33_56_34694=null;
var title_f33_56_34695="Argon plasma coagulation in the management of gastrointestinal hemorrhage";
var content_f33_56_34695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     Jonathan Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34695/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/56/34695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Argon plasma coagulation (APC) is a non-contact thermal method of hemostasis that has generated much attention and excitement in recent years. It was introduced as an alternative to contact thermal coagulation (heater probe and bipolar cautery) and to existing non-contact technologies (primarily laser). The theoretical advantages of APC include its ease of application, speedy treatment of multiple lesions in the case of angiodysplasias or wide areas (the base of resected polyps or tumor bleeding), safety due to reduced depth of penetration, and lower cost compared to laser.",
"   </p>",
"   <p>",
"    This topic will review argon plasma coagulation, including how it is used and its efficacy. The general management of adult patients with upper and lower gastrointestinal bleeding, as well as a detailed discussion of angiodysplasia of the gastrointestinal tract are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHAT IS APC?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrary to a common misconception, argon plasma coagulation (APC) is",
"    <strong>",
"     not",
"    </strong>",
"    a laser. This technology uses argon gas to deliver plasma of evenly distributed thermal energy to a field of tissue adjacent to the probe. A high voltage spark is delivered at the tip of the probe that ionizes the argon gas as it is sprayed from the probe tip in the direction of the target tissue. Argon gas is non-flammable and inexpensive to refill. It is easily ionized by the 6000 volt peak energy delivered by the tungsten wire that terminates just proximal to the probe tip. This ionized gas or plasma then seeks a ground in the nearest tissue, delivering the thermal energy with a depth of penetration of roughly 2 to 3 mm. The plasma coagulates both linearly and tangentially. By delivering energy to all tissue near the probe tip, APC can be used to treat a lesion around a fold and not clearly in view or a lesion that cannot be positioned directly in front of the endoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar technology has been used for many years by surgeons in the operating room, particularly during hepatic surgery, as a means of spray coagulation to control superficial, diffuse bleeding. In the early 1990s, special probes were developed by the ERBE Corp. to allow this technology to be applied to flexible endoscopy. The disposable probes are available with diameters of 1.5 mm, 2.3 mm (the most commonly used size), and 3.2 mm. The standard probes are 220 cm long (",
"    <a class=\"graphic graphic_picture graphicRef72597 \" href=\"mobipreview.htm?0/19/319\">",
"     picture 1",
"    </a>",
"    ); 300 cm probes can be specially ordered for use during push enteroscopy.",
"   </p>",
"   <p>",
"    In addition to the probe, the equipment consists of an electrosurgical generator that comes on a cart along with the argon plasma coagulator, a foot pedal, and two tanks of argon gas. Both the argon flow rate and the wattage delivered per pulse are easily adjusted by pressing buttons on the control panel. Newer models of this cart will include a water pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Argon plasma coagulation (APC) is easy to perform and can generally be learned in a few proctored sessions. No special safety precautions are necessary for the operator.",
"   </p>",
"   <p>",
"    When the endoscopist identifies a lesion suitable for APC, a grounding pad is placed on the patient's thigh or shoulder. The argon gas from one of the tanks is turned on and the generator and coagulator power is switched on. A flow rate (generally 0.8 to 1.0",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    of argon is selected. It is important to recognize that although argon gas only flows through the probe in pulses when the foot pedal is applied, significant insufflation of the bowel lumen can occur with repeated applications unless the gas is suctioned periodically via the endoscope. Continuous suction is not required.",
"   </p>",
"   <p>",
"    The power setting on the APC2 current generator is adjusted based upon the location of the lesion. Lower settings, in the range of 20 to 30 watts, are used in thinner regions of the gastrointestinal tract, such as the colon and small bowel. Higher settings (30 to 40 watts) are used for the thicker-walled stomach and for tumor ablation. Depth of penetration during coagulation depends upon the wattage and the number of pulses at a particular location. Areas of previous coagulation have greater impedance, so subsequent pulses favor adjacent uncoagulated tissue. However, deeper penetration may occur from extra pulses in the same area.",
"   </p>",
"   <p>",
"    The electrosurgical generator allows several settings to be pre-programmed. The anatomic location can be selected (eg, right colon, stomach, etc), as well as the intended therapy (eg, soft coagulation, polypectomy, endoscopic mucosal resection). Each pre-programmed function has default power and delivery modes appropriate for the indication. In addition, the endoscopist may manually adjust the settings if desired. We strongly advise all endoscopists to familiarize themselves and their assistants with the use and adjustment of their electrosurgical generators prior to use.",
"   </p>",
"   <p>",
"    Before use, the apparatus is tested by directing the probe to a special test target that fits into the grounding socket on the generator. Before inserting the probe into the biopsy channel of the endoscope, the operator presses the purge button on the coagulator to prime the probe with argon.",
"   </p>",
"   <p>",
"    The probe is passed via the endoscope's accessory channel so that the blue tip hovers over the target tissue. A black stripe located a few centimeters proximal to the tip should be visible to ensure that the probe protrudes sufficiently. If the tip of the probe is too close to the endoscope it could result in damage to the scope. Generally, the ionized plasma will only reach tissue if it is fired less than 1 cm from the target. Since APC occurs with slightly different efficiency in different patients and in different locations within the bowel, we recommend calibrating the coagulator with the first pulse. This is done by intentionally firing a pulse when the probe is too far away from the tissue to deliver any coagulation. The endoscopist fires subsequent pulses while gradually moving the probe closer to the tissue until coagulation occurs. In this way, the endoscopist can identify the furthest possible distance at which APC can be performed for a particular target.",
"   </p>",
"   <p>",
"    It is important not to fire too close to the target. If the probe touches the mucosa directly when firing, the coagulation is direct rather than via ionizing plasma and a deeper injury similar to monopolar electrocautery results. For this reason, we find the calibration technique described above to be particularly helpful in the right colon. In some cases, such as ablation of residual polyp tissue or tumor, deeper coagulation may be desirable. This can be achieved by applying longer periods of APC to a particular area, but care should still be exercised to avoid coming into direct contact with the tissue.",
"   </p>",
"   <p>",
"    APC may be fired either in a continuous \"forced\" mode, in which the plasma is delivered as long as the foot pedal is depressed, or in a pulsed mode, in which very short bursts of APC are delivered. Specifically, the following three modes are available on the current VIO",
"    <span class=\"nowrap\">",
"     300D/APC",
"    </span>",
"    2 system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forced APC is the \"old fashioned\" continuous delivery mode.",
"     </li>",
"     <li>",
"      Pulsed APC fires intermittently and has two pulse speeds:&nbsp;Pulsed Effect 1 with half-second bursts and Pulsed Effect 2 with rapid bursts that occur 16 times per second. The pulsed mode is a particularly useful strategy when only very superficial treatment of an area is desired, as in coagulation of an angiodysplasia.",
"     </li>",
"     <li>",
"      Precise APC is a continuous delivery mode, but also offers plasma regulation so that the energy delivery adjusts to become more or less intense as tissue resistance changes.&nbsp;The Precise mode tends to be very homogenous and offers more control over the depth of penetration during APC delivery compared with the other modes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The probe can be used to coagulate discrete lesions with isolated pulses or may be used to \"paint\" areas with multiple lesions (eg, in the treatment of gastric antral vascular ectasias or radiation proctopathy). Painting is performed either by dragging the endoscope with the probe in a fixed position or by swinging the probe by deflecting the endoscope tip in a pendulum fashion. Charring of the probe is generally less than is seen with contact thermal devices, but may occur when direct tissue contact is made. Occasionally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    may be helpful to reduce bowel motility and facilitate treatment of multiple lesions.",
"   </p>",
"   <p>",
"    Care should be taken to avoid excessive insufflation, particularly in the colon. While there is less smoke generated than with laser therapies, it can still obscure visualization. Intermittent suction serves to prevent over-insufflation while also clearing the field of view.",
"   </p>",
"   <p>",
"    Superficial ulceration occurs following APC, which typically heals within two to three weeks. Despite theoretical safety advantages due to reduced depth of penetration, all of the complications that have been reported with other thermal hemostasis techniques can occur. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY FOR GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first series of clinical applications of argon plasma coagulation (APC) in gastrointestinal (GI) endoscopy was published in 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/1\">",
"     1",
"    </a>",
"    ]. Forty-eight of the initial 189 applications were done to control bleeding either from tumors or from a variety of other sites. While no specific data were provided to assess outcome for GI bleeding, the authors described the technique as successful and without complications. Their largely qualitative description cites facility in treating tangential lesions, lack of smoke, and safety as key advantages compared with other techniques.",
"   </p>",
"   <p>",
"    Several centers have subsequently reported experience with this technique in the management of GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. However, few randomized comparisons to other hemostasis techniques have been performed. A meta-analysis identified only two controlled trials (with a total of 121 patients) comparing APC with other endoscopic hemostasis interventions (heater probe and injection sclerotherapy) in the treatment of non-variceal upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/9\">",
"     9",
"    </a>",
"    ]. No significant differences were observed in either study.",
"   </p>",
"   <p>",
"    A technology assessment report from the American Society for Gastrointestinal Endoscopy concluded that APC was best suited for hemostasis of diffuse superficial vascular lesions, such as gastric antral vascular ectasia syndrome and radiation induced proctopathy, but that there were insufficient comparative data to assess its performance relative to other modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Angiodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy and superficial location of angiodysplasia make them well suited for APC treatment. Immediate hemostasis rates range from 85 to 100 percent in various reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/5,6,11-14\">",
"     5,6,11-14",
"    </a>",
"    ] and treatment can result in long-term control of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special considerations warrant comment regarding APC for angiodysplasia. Bowel motility can be problematic, particularly in the small bowel. As mentioned above, most authors find that the ease of tangential treatment and decreased smoke are advantages to APC compared with contact techniques (",
"    <a class=\"graphic graphic_picture graphicRef79901 \" href=\"mobipreview.htm?17/47/18164\">",
"     picture 2",
"    </a>",
"    ). A disadvantage is the inability to irrigate directly through the probe. APC does not work well if the targeted lesion is under water.",
"   </p>",
"   <p>",
"    A number of recommendations can be made based upon clinical experience:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjust wattage downward for targets with thinner walls.",
"     </li>",
"     <li>",
"      Calibrate the optimal distance to avoid undesired contact coagulation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treat the center of the angiodysplasia; complete whitening of the area is not always needed and multiple pulses applied to the same tissue may result in unintentional deep penetration.",
"     </li>",
"     <li>",
"      Frequently suction gas to avoid over-insufflation, particularly in the colon.",
"     </li>",
"     <li>",
"      Avoid getting the probe tip wet. Press the purge button when this happens.",
"     </li>",
"     <li>",
"      Wash the lesion to identify the bleeding site, but realize that APC is difficult for lesions that are under a pool of water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Watermelon stomach/GAVE syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial treatments with APC can reduce transfusion requirements and raise hemoglobin in patients with gastric antral vascular ectasia (GAVE) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In most series, the number of sessions required to reduce blood loss was lower than the number of sessions required in published series of treating watermelon stomach using laser and bipolar techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Most patients required three to four sessions to achieve the desired clinical benefit. However, long-term follow-up data are limited.",
"   </p>",
"   <p>",
"    Ulcers commonly occur following therapy, although they are rarely symptomatic. At least two weeks should be allowed between treatments to allow ulcers to heal (",
"    <a class=\"graphic graphic_picture graphicRef74688 \" href=\"mobipreview.htm?32/44/33473\">",
"     picture 3",
"    </a>",
"    ). We also typically place patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    and proton pump inhibitor. Hyperplastic polyp formation following gastric APC has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation telangiectasias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of methods have been described for controlling bleeding in patients with radiation telangiectasias (also referred to as radiation proctopathy or radiation proctitis), including APC (",
"    <a class=\"graphic graphic_picture graphicRef64264 \" href=\"mobipreview.htm?33/51/34608\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .) The efficacy of APC has been suggested in several case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/4,21,22\">",
"     4,21,22",
"    </a>",
"    ]. One of the largest reports included 28 patients with persistent bleeding despite medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/4\">",
"     4",
"    </a>",
"    ]. The majority of patients had improvement in bleeding and anemia after a median of 2.9 sessions (range 1 to 8). All visible lesions were targeted at each session and follow-up procedures were scheduled in four-week intervals to allow the tissue to heal. The mean hemoglobin rose by 1.2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and by 1.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    among individuals presenting with anemia. Some patients experienced post-procedure rectal pain and cramps, but no major complications occurred. Other reports have demonstrated that APC may control bleeding even after unsuccessful treatment using other methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study that included 50 patients examined the safety and efficacy of a single large-volume APC application for the treatment of chronic radiation proctitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/23\">",
"     23",
"    </a>",
"    ]. APC was applied with the goal of ablating all visible telangiectasias during a single endoscopic procedure. Treatment was considered successful if there was no rectal bleeding or only minor, intermittent rectal bleeding following treatment. A single treatment session was successful in 34 patients (68 percent). Fourteen patients (28 percent) were successfully treated after a second session.",
"   </p>",
"   <p>",
"    Special care is required to avoid spraying too close to the dentate line. 5-ASA suppositories",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Cortifoam enemas are often used to help treat procedure-induced rectal ulcers, which occur in more than one-half of patients but are usually asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/24\">",
"     24",
"    </a>",
"    ]. Residual ulcers seen during a follow-up examination should be avoided during subsequent treatment.",
"   </p>",
"   <p>",
"    A complete bowel lavage is probably safest before each procedure. A potential complication if this is not done is bowel explosion with perforation, presumably due to the accumulation of combustible colonic gas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Piecemeal polypectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;APC has been used to coagulate the base of large sessile polyps, which can eliminate residual adenomatous tissue and can assist in the control of minor bleeding (",
"    <a class=\"graphic graphic_picture graphicRef72550 \" href=\"mobipreview.htm?36/24/37251\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. A controlled trial suggested that it may decrease recurrence following piecemeal resection of large (&gt;1.5 cm) sessile adenomas that were considered to have been completely removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tumor debulking and bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;APC is widely used as an alternative to laser and bipolar cautery to debulk tumors, to treat tumor ingrowth in stents, and to control generalized bleeding from tumors, although no large series have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/5,28-31\">",
"     5,28-31",
"    </a>",
"    ]. Most of the experience with APC has been to debulk tumors and thereby relieve obstruction and dysphagia. APC can also be used to temporarily manage bleeding, although it often does not have long-term benefits. However, it has an advantage compared with other methods to temporarily control bleeding since it can rapidly coagulate a relatively wide area.",
"   </p>",
"   <p>",
"    One of the largest series included 83 patients with inoperable esophageal or gastric cardia cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/28\">",
"     28",
"    </a>",
"    ]. APC achieved recanalization permitting passage of normal food in 48 patients (58 percent) after one session and an additional 22 patients (84 percent) after two sessions. The remaining patients had improvement in dysphagia. Perforation occurred in seven patients, all but one of whom were treated conservatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ulcer hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic treatment of serious ulcer bleeding with active spurting or non-bleeding visible vessels is usually accomplished with mechanical or thermal tamponade techniques, with or without epinephrine injection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is theoretical concern that firm pressure is an important aspect of contact thermal hemostasis of non-bleeding visible vessels, particularly with a larger diameter. However, one small randomized comparison of 41 patients showed similar rates of hemostasis with use of the heater probe or APC alone for actively bleeding and non-bleeding visible vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/32\">",
"     32",
"    </a>",
"    ]. This finding awaits confirmation by other, larger studies.",
"   </p>",
"   <p>",
"    APC appears to be effective as part of combination therapy for visible vessels. A controlled trial involving 192 patients found that APC plus epinephrine injection was as safe and effective as epinephrine injection plus heater probe coagulation in patients with high-risk bleeding peptic ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Esophageal varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited preliminary experience suggests a possible role of APC combined with variceal band ligation in the treatment of esophageal varices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dieulafoy's lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case series described successful treatment of Dieulafoy's lesions (mainly in the upper gastrointestinal tract) with APC alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Argon plasma coagulation (APC) has a theoretical safety advantage over other modalities due to its decreased depth of penetration and the tendency for the ionized arc of electrical current to deflect away from coagulated tissue to surrounding areas. However, like any coagulation method, serious complications can occur, particularly in the right colon. The perforation rate in one large series was 6 out of 2193 sessions (0.2 percent) in 1062 patients. The authors reported 10 minor complications, most commonly subcutaneous emphysema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/3\">",
"     3",
"    </a>",
"    ]. Isolated perforations have occurred in other series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/2,35\">",
"     2,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications that have been observed are asymptomatic and symptomatic pneumoperitoneum and subcutaneous bubbling of gas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. It is likely that these problems are caused by either over-distension within the cecum or unintentional direct contact of the probe to the thin bowel wall during pulses resulting in deeper monopolar cautery. No treatment is generally required when the subcutaneous bubbling of gas is observed.",
"   </p>",
"   <p>",
"    A potential complication in patients undergoing colonic procedures who did not receive a full colonic lavage (such as those receiving APC for radiation proctopathy) is bowel explosion with perforation, presumably due to the accumulation of combustible colonic gas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPARISONS BETWEEN TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, few studies have directly compared argon plasma coagulation (APC) to other methods for achieving hemostasis. A systematic review published in 2005 identified only two randomized controlled trials (with only 121 individuals) in non-variceal upper GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34695/abstract/9\">",
"     9",
"    </a>",
"    ]. However, APC is used widely due to its ease of use and perceived safety advantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/54/41826?source=see_link\">",
"       \"Patient information: Angiodysplasia of the GI tract (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopists experienced with argon plasma coagulation (APC) generally find it to be helpful for targets that are difficult to reach by direct contact and for treating multiple lesions at the same session. In addition, APC tends to be quicker than contact thermal therapies. There have been few trials comparing APC to other endoscopic methods used for similar indications. The availability of the necessary equipment and familiarity with specific methods are important considerations when choosing options. We suggest APC be used in the following settings (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeted therapy of isolated angiodysplasia in the colon, small bowel, and stomach",
"     </li>",
"     <li>",
"      Treatment of gastric antral vascular ectasia",
"     </li>",
"     <li>",
"      Treatment of radiation telangiectasia (also referred to as radiation proctopathy or radiation proctitis) with significant or symptomatic bleeding",
"     </li>",
"     <li>",
"      Postpolypectomy for large sessile polyps to fulgurate the base to reduce recurrent adenoma",
"     </li>",
"     <li>",
"      Ablation of flat residual duodenal or colon polyps in hard to reach locations that cannot be removed with a snare",
"     </li>",
"     <li>",
"      Treatment of tumor ingrowth into esophageal metal stents",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/1\">",
"      Grund KE, Storek D, Farin G. Endoscopic argon plasma coagulation (APC) first clinical experiences in flexible endoscopy. Endosc Surg Allied Technol 1994; 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/2\">",
"      Wahab PJ, Mulder CJ, den Hartog G, Thies JE. Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/3\">",
"      Herrera S, Bordas JM, Llach J, et al. The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage. Gastrointest Endosc 2008; 68:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/4\">",
"      Silva RA, Correia AJ, Dias LM, et al. Argon plasma coagulation therapy for hemorrhagic radiation proctosigmoiditis. Gastrointest Endosc 1999; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/5\">",
"      Johanns W, Luis W, Janssen J, et al. Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences. Eur J Gastroenterol Hepatol 1997; 9:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/6\">",
"      Fantin AC, Binek J, Suter WR, Meyenberger C. Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 1999; 49:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/7\">",
"      Fazel A, Presti ME, Saeed ZA. Utility of the argon plasma coagulator: A university hospital experience (abstract). Gastrointest Endosc 1999; 49:AB123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/8\">",
"      Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc 2004; 59:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/9\">",
"      Havanond C, Havanond P. Argon plasma coagulation therapy for acute non-variceal upper gastrointestinal bleeding. Cochrane Database Syst Rev 2005; :CD003791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/10\">",
"      Ginsberg GG, Barkun AN, Bosco JJ, et al. The argon plasma coagulator: February 2002. Gastrointest Endosc 2002; 55:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/11\">",
"      Kwan V, Bourke MJ, Williams SJ, et al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol 2006; 101:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/12\">",
"      Shudo R, Yazaki Y, Sakurai S, et al. Diffuse antral vascular ectasia: EUS after argon plasma coagulation. Gastrointest Endosc 2001; 54:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/13\">",
"      Rolachon A, Papillon E, Fournet J. [Is argon plasma coagulation an efficient treatment for digestive system vascular malformation and radiation proctitis?]. Gastroenterol Clin Biol 2000; 24:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/14\">",
"      Kitamura T, Tanabe S, Koizumi W, et al. Rendu-Osler-Weber disease successfully treated by argon plasma coagulation. Gastrointest Endosc 2001; 54:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/15\">",
"      Probst A, Scheubel R, Wienbeck M. Treatment of watermelon stomach (GAVE syndrome) by means of endoscopic argon plasma coagulation (APC): long-term outcome. Z Gastroenterol 2001; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/16\">",
"      Yusoff I, Brennan F, Ormonde D, Laurence B. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002; 34:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/17\">",
"      Gostout CJ, Ahlquist DA, Radford CM, et al. Endoscopic laser therapy for watermelon stomach. Gastroenterology 1989; 96:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/18\">",
"      Gostout CJ, Viggiano TR, Ahlquist DA, et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/19\">",
"      Petrini JL Jr, Johnston JH. Heat probe treatment for antral vascular ectasia. Gastrointest Endosc 1989; 35:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/20\">",
"      Schmeck-Lindenau HJ, Kurtz W, Heine M. Inflammatory polyps: an unreported side effect of argon plasma coagulation. Endoscopy 1998; 30:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/21\">",
"      Tjandra JJ, Sengupta S. Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 2001; 44:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/22\">",
"      Ta&iuml;eb S, Rolachon A, Cenni JC, et al. Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 2001; 44:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/23\">",
"      Swan MP, Moore GT, Sievert W, Devonshire DA. Efficacy and safety of single-session argon plasma coagulation in the management of chronic radiation proctitis. Gastrointest Endosc 2010; 72:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/24\">",
"      Ravizza D, Fiori G, Trovato C, Crosta C. Frequency and outcomes of rectal ulcers during argon plasma coagulation for chronic radiation-induced proctopathy. Gastrointest Endosc 2003; 57:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/25\">",
"      Ben Soussan E, Mathieu N, Roque I, Antonietti M. Bowel explosion with colonic perforation during argon plasma coagulation for hemorrhagic radiation-induced proctitis. Gastrointest Endosc 2003; 57:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/26\">",
"      Zlatanic J, Waye JD, Kim PS, et al. Large sessile colonic adenomas: use of argon plasma coagulator to supplement piecemeal snare polypectomy. Gastrointest Endosc 1999; 49:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/27\">",
"      Brooker JC, Saunders BP, Shah SG, et al. Treatment with argon plasma coagulation reduces recurrence after piecemeal resection of large sessile colonic polyps: a randomized trial and recommendations. Gastrointest Endosc 2002; 55:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/28\">",
"      Heindorff H, W&oslash;jdemann M, Bisgaard T, Svendsen LB. Endoscopic palliation of inoperable cancer of the oesophagus or cardia by argon electrocoagulation. Scand J Gastroenterol 1998; 33:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/29\">",
"      Sessler MJ, Becker HD, Flesch I, Grund KE. Therapeutic effect of argon plasma coagulation on small malignant gastrointestinal tumors. J Cancer Res Clin Oncol 1995; 121:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/30\">",
"      Akhtar K, Byrne JP, Bancewicz J, Attwood SE. Argon beam plasma coagulation in the management of cancers of the esophagus and stomach. Surg Endosc 2000; 14:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/31\">",
"      Robertson GS, Thomas M, Jamieson J, et al. Palliation of oesophageal carcinoma using the argon beam coagulator. Br J Surg 1996; 83:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/32\">",
"      Cipolletta L, Bianco MA, Rotondano G, et al. Prospective comparison of argon plasma coagulator and heater probe in the endoscopic treatment of major peptic ulcer bleeding. Gastrointest Endosc 1998; 48:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/33\">",
"      Chau CH, Siu WT, Law BK, et al. Randomized controlled trial comparing epinephrine injection plus heat probe coagulation versus epinephrine injection plus argon plasma coagulation for bleeding peptic ulcers. Gastrointest Endosc 2003; 57:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/34\">",
"      Iacopini F, Petruzziello L, Marchese M, et al. Hemostasis of Dieulafoy's lesions by argon plasma coagulation (with video). Gastrointest Endosc 2007; 66:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/35\">",
"      Conio M, Gostout CJ. Argon plasma coagulation (APC) in gastroenterology experimental and clinical experiences. Gastrointest Endosc 1998; 48:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/36\">",
"      Tan AC, Schellekens PP, Wahab P, Mulder CJ. Pneumatosis intestinalis, retroperitonealis, and thoracalis after argon plasma coagulation. Endoscopy 1995; 27:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34695/abstract/37\">",
"      Hoyer N, Thouet R, Zellweger U. Massive pneumoperitoneum after endoscopic argon plasma coagulation. Endoscopy 1998; 30:S44.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2576 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-201.211.0.116-4DD8AB15FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34695=[""].join("\n");
var outline_f33_56_34695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHAT IS APC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY FOR GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Angiodysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Watermelon stomach/GAVE syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation telangiectasias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Piecemeal polypectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tumor debulking and bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ulcer hemostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dieulafoy's lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPARISONS BETWEEN TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2576|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/19/319\" title=\"picture 1\">",
"      APC probe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/47/18164\" title=\"picture 2\">",
"      AVMs APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/44/33473\" title=\"picture 3\">",
"      GAVE APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/51/34608\" title=\"picture 4\">",
"      XRT proctitis APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/24/37251\" title=\"picture 5\">",
"      Polypectomy APC Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35689?source=related_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/54/41826?source=related_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34696="Usual interstitial pneumonia CT";
var content_f33_56_34696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80665%7EPULM%2F82237%7EPULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80665%7EPULM%2F82237%7EPULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Usual interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exudative phase of UIP with ground glass and consolidative changes. No definite honeycombing is present. Subpleural curvilinear lines and mild traction bronchiectasis are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Honeycomb cysts in IPF/UIP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Idiopathic pulmonary fibrosis/usual interstitial pneumonia with bilateral, small subpleural honeycomb cysts which are separated by normal parenchyma. The anterior segmental bronchus of the left upper lobe is slightly dilated, consistent with mild traction bronchiectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marked honeycombing in IPF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Usual interstitial pneumonia pattern with marked honeycombing and traction bronchiectasis in both lower lobes along with an absence of ground glass changes. The peripheral regions of the lower lobes and middle lobe are typically involved, initially sparing the central parts of the lower lobes.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34696=[""].join("\n");
var outline_f33_56_34696=null;
var title_f33_56_34697="Etiology, diagnosis, and treatment of secondary amenorrhea";
var content_f33_56_34697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, diagnosis, and treatment of secondary amenorrhea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34697/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/56/34697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amenorrhea (absence of menses) can be a transient, intermittent, or permanent condition resulting from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina (",
"    <a class=\"graphic graphic_table graphicRef59801 \" href=\"mobipreview.htm?1/19/1340\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73995 \" href=\"mobipreview.htm?25/25/26012\">",
"     table 2",
"    </a>",
"    ). It is often classified as either primary (absence of menarche by age 15 years) or secondary (absence of menses for more than three cycles or six months in women who previously had menses). The menstrual cycle is susceptible to outside influences; thus, missing a single menstrual period is rarely important. In contrast, prolonged amenorrhea may be the earliest sign of a decline in general health or signal an underlying condition such as hypothyroidism.",
"   </p>",
"   <p>",
"    The causes and diagnosis of secondary amenorrhea and a brief summary of treatment options are reviewed here. The etiologic and diagnostic considerations for",
"    <strong>",
"     oligomenorrhea",
"    </strong>",
"    are the same as for amenorrhea. Primary amenorrhea is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195280\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is the most common cause of secondary amenorrhea. It may occur even in women who claim that they have not been sexually active or are positive that intercourse occurred at a \"safe\" time. It is also important to note that apparent menstrual bleeding does not exclude pregnancy, since a substantial number of pregnancies are associated with some early first trimester bleeding. Thus, a pregnancy test (measurements of serum or urinary human chorionic gonadotropin [hCG]) is recommended as a first step in evaluating any woman with amenorrhea. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once pregnancy has been ruled out, a logical approach to women with either primary or secondary amenorrhea is to consider disorders based upon the levels of control of the menstrual cycle: hypothalamus, pituitary, ovary, and uterus. The most common causes of secondary amenorrhea are disorders of the [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ovary &mdash; 40 percent",
"     </li>",
"     <li>",
"      Hypothalamus &mdash; 35 percent",
"     </li>",
"     <li>",
"      Pituitary &mdash; 19 percent",
"     </li>",
"     <li>",
"      Uterus &mdash; 5 percent",
"     </li>",
"     <li>",
"      Other &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypothalamic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most common types of secondary amenorrhea is functional hypothalamic amenorrhea, which by definition excludes pathologic disease. Although rare, infiltrative diseases of the hypothalamus can cause secondary amenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H132363\">",
"    <span class=\"h3\">",
"     Congenital GnRH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sometimes erroneously considered in the differential diagnosis of secondary amenorrhea, congenital GnRH deficiency presents as primary amenorrhea. There have been some reports of a single menstrual bleed in selected cases (eg, with GnRH receptor mutations, which may not cause complete receptor dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/3\">",
"     3",
"    </a>",
"    ]). It is called idiopathic hypogonadotropic hypogonadism or, if it is associated with anosmia, Kallmann syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder is genetically heterogeneous; mutations in genes such as KAL1, FGFR1, GNRHR1, and PROKR2 have been described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Functional hypothalamic amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional hypothalamic amenorrhea, or functional hypothalamic GnRH deficiency, is a disorder that, by definition, excludes pathologic disease. It is characterized by a decrease in hypothalamic gonadotropin-releasing hormone (GnRH) secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abnormal GnRH secretion characteristic of functional hypothalamic amenorrhea leads to decreased pulses of gonadotropins, absent midcycle surges in luteinizing hormone (LH) secretion, absence of normal follicular development, anovulation, and low serum estradiol concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/6\">",
"     6",
"    </a>",
"    ]. Variable neuroendocrine patterns of LH secretion can be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/7\">",
"     7",
"    </a>",
"    ]. Serum concentrations of follicle-stimulating hormone (FSH) often exceed those of LH, similar to the pattern in prepubertal girls.",
"   </p>",
"   <p>",
"    One of the main clinical concerns in women with functional hypothalamic amenorrhea is bone loss due to hypoestrogenemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H132066\">",
"    <span class=\"h4\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors may contribute to the pathogenesis of functional hypothalamic amenorrhea, including eating disorders (such as anorexia nervosa), exercise, and stress. However, in a few women with functional hypothalamic amenorrhea, no obvious precipitating factor is evident. The term hypothalamic amenorrhea (HA) is often used interchangeably with functional hypothalamic amenorrhea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both weight loss below a certain target level (approximately 10 percent below ideal body weight) and",
"      <strong>",
"       exercise",
"      </strong>",
"      are associated with amenorrhea. Most cases of amenorrhea associated with exercise are also associated with weight loss, with evidence that caloric intake sufficient to match the energy expenditure enables normal cycles to be maintained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The \"female athlete triad\" is defined as the presence of amenorrhea, disordered eating, and osteoporosis or osteopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/10\">",
"       10",
"      </a>",
"      ]. This syndrome is especially common in amenorrhea associated with ballet dancing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"       \"Amenorrhea and infertility associated with exercise\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothalamic amenorrhea can be caused by",
"      <strong>",
"       nutritional deficiencies",
"      </strong>",
"      that are not associated with weight loss or strenuous exercise. As an example, in two studies, the diet and body composition of nonathletic women with hypothalamic amenorrhea and normal body mass index were compared with similar women who had regular menstrual cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In contrast to their menstruating counterparts, the women with amenorrhea severely restricted their fat consumption and had lower body fat mass. Another example of amenorrhea due to nutritional deficiencies is celiac disease. (See",
"      <a class=\"local\" href=\"#H464655922\">",
"       'Celiac disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Emotional",
"      <strong>",
"      </strong>",
"      stress and stress induced by illness (eg, myocardial infarction, severe burns) are additional causes of hypothalamic amenorrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172207980\">",
"    <span class=\"h4\">",
"     Role of leptin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypothalamic amenorrhea have lower serum concentrations of leptin, a protein that probably contributes to their low gonadotropin secretion as compared with similar-weight women who have normal menstrual cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The chronic energy deficit and hypoleptinemia seen with HA is also associated with bone loss and neuroendocrine dysfunction, including abnormalities of the thyroid, growth hormone, and adrenal axes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/10-13,15\">",
"     10-13,15",
"    </a>",
"    ]. In one study of eight women with functional hypothalamic amenorrhea, recombinant leptin administration resulted in improvement of the reproductive axis (increased mean serum LH concentrations and pulsatility), increased serum estradiol, and ovulation in three of eight women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/16\">",
"     16",
"    </a>",
"    ]. Other effects included increases in free T3, free T4, insulin-like growth factor 1 (IGF1), and osteocalcin. This pilot study suggested that leptin administration in women with HA improved the reproductive, thyroid, and growth hormone axes, as well as markers of bone formation. (See",
"    <a class=\"local\" href=\"#H180195634\">",
"     'Hypothalamic amenorrhea'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link&amp;anchor=H13#H13\">",
"     \"Physiology of leptin\", section on 'Hypothalamic amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H132415\">",
"    <span class=\"h4\">",
"     Genetic basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is marked interpatient variability in the degree of weight loss or exercise required to induce amenorrhea. This may in part be due to an underlying genetic predisposition in susceptible individuals. A number of gene mutations have been identified in patients with congenital GnRH deficiency; heterozygous mutations in some of the same genes (KAL1, FGFR1, PROKR2, GNRHR) have now been identified in women with functional hypothalamic amenorrhea, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H132363\">",
"     'Congenital GnRH deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195287\">",
"    <span class=\"h4\">",
"     Recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of hypothalamic amenorrhea (HA) has been studied in a retrospective, questionnaire-based analysis of 28 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/18\">",
"     18",
"    </a>",
"    ]. Women with a history of HA with a clear precipitant (eating disorder, stress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss) had a better prognosis for recovery than those with no clear precipitant (71 and 29 percent, respectively). Reversal of the inciting factor appeared necessary but not sufficient for recovery (83 percent recovery if factor reversed). In a second study of 93 women with hypothalamic amenorrhea, baseline predictors of recovery included a higher BMI and serum androstenedione concentration, and a lower serum cortisol concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Infiltrative lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrative diseases of the hypothalamus (eg, lymphoma, Langerhans cell histiocytosis, sarcoidosis) may result in decreased GnRH secretion, low or normal serum gonadotropin concentrations, and amenorrhea. However, these lesions are rare compared with functional hypothalamic amenorrhea. Most women with infiltrative disease of the hypothalamus who have amenorrhea will have one or more neurologic symptoms, such as severe headache, change in personality, or marked mood changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic sarcoidosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link&amp;anchor=H452648890#H452648890\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Diabetes insipidus and other endocrinopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464655914\">",
"    <span class=\"h3\">",
"     Systemic illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic illness may be associated with menstrual cycle disorders when it is severe enough to result in a decrease in hypothalamic GnRH secretion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when it is associated with nutritional deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464655922\">",
"    <span class=\"h4\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that approximately 40 percent of women with untreated celiac disease have menstrual cycle disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/20\">",
"     20",
"    </a>",
"    ]. Other reproductive problems in these women include delayed menarche, infertility, miscarriage, and pregnancy complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H33#H33\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Menstrual and reproductive issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pituitary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lactotroph adenoma (prolactin-secreting pituitary tumor, prolactinoma) is responsible for almost 20 percent of cases of secondary amenorrhea and is the most common (90 percent) pituitary etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/1\">",
"     1",
"    </a>",
"    ]. Other types of pituitary adenomas and other sellar masses, and other types of pituitary disease, account for the majority of the remaining cases of pituitary origin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia has a similar presentation to functional hypothalamic amenorrhea except for the occasional additional finding of galactorrhea in some women. As a result, serum prolactin should be measured in every woman with amenorrhea. The normal range should be consulted for the prolactin assay used, as the upper limit of normal for women of reproductive age can range from 20 to 27",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (20 to 27",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    Stress, sleep, intercourse, meals, and nipple stimulation can also raise serum prolactin. Thus, we recommend that serum prolactin be measured at least twice before sellar imaging is ordered, particularly in women with borderline high values (&lt;50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;50",
"    <span class=\"nowrap\">",
"     mcg/L]).",
"    </span>",
"   </p>",
"   <p>",
"    Prolactin",
"    appears to cause amenorrhea by suppressing hypothalamic GnRH secretion, leading to low gonadotropin and estradiol concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/21\">",
"     21",
"    </a>",
"    ]. Unlike the other pituitary hormones, prolactin release is mostly controlled by inhibition, primarily by hypothalamic dopamine. The negative regulation by dopamine is so potent that disruption of the pituitary stalk, by trauma or a large tumor, leads to hyperprolactinemia. Several drugs, estrogen, and increased thyrotropin-releasing hormone release due to hypothyroidism can also reversibly stimulate prolactin secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important cause of persistent hyperprolactinemia is a lactotroph adenoma (prolactin-secreting pituitary tumor, prolactinoma). Magnetic resonance imaging (MRI) of the pituitary should therefore be performed in any woman with persistent hyperprolactinemia. As a general rule, the serum prolactin concentration correlates with pituitary tumor size. Thus, a minimal increase in serum prolactin concentration in a woman with a large tumor suggests that the mass is probably not a prolactinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other sellar masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any other sellar mass (such as other kinds of pituitary adenomas, craniopharyngiomas, meningiomas, cysts, etc) can also cause deficient gonadotropin secretion and therefore amenorrhea, with or without hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other diseases of the pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sheehan's syndrome, radiation, infarction, and infiltrative lesions of the pituitary gland, such as hemochromatosis, and lymphocytic hypophysitis, are all uncommon causes of gonadotropin deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .) Iron studies to test for hemochromatosis should be performed if there is an appropriate family history or if the woman has manifestations of iron overload such as bronzed skin, diabetes mellitus, or unexplained heart or liver disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary amenorrhea can be caused by primary hypothyroidism, although not as commonly as menometrorrhagia. It is important to recognize hypothyroidism as a potential cause of an enlarged pituitary gland (due to thyrotroph hyperplasia, lactotroph hyperplasia, or both) and hyperprolactinemia, and not to confuse this entity with a lactotroph adenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of hypothyroidism\", section on 'Reproductive abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Menstrual cycle disorders are common in women with thyroid disease. This was illustrated in a report of over 1000 women with a thyroid disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/24\">",
"     24",
"    </a>",
"    ]. In women with severe hyperthyroidism, amenorrhea and hypomenorrhea occurred in 2.5 and 3.7 percent, respectively. Rates were lower in those with mild to moderate hyperthyroidism (0.2 and 0.9 percent, respectively). Menstrual disturbances were more common in women with hypothyroidism (35 and 10 percent for severe and mild-moderate hypothyroidism, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of hypothyroidism\", section on 'Reproductive abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ovarian disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major disorders in this category include polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (premature ovarian failure). Of note, PCOS is not simply an ovarian disorder; its pathogenesis is complex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome, one of the most common endocrine disorders in women, accounts for approximately 20 percent of cases of amenorrhea. The principal features of PCOS include androgen excess, ovulatory dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polycystic ovaries. Women with PCOS may present with amenorrhea, but they more commonly have irregular menses (oligomenorrhea). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The minimal criteria for the diagnosis of PCOS are two out of three of the following: (1) hyperandrogenism, (2) oligomenorrhea or amenorrhea, and (3) polycystic ovaries on ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/25\">",
"     25",
"    </a>",
"    ]. Hyperandrogenism is usually manifested clinically as acne or hirsutism and sometimes as a high serum concentration of at least one androgen. PCOS is a diagnosis of exclusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperandrogenism alone (endogenous or exogenous) may cause menstrual cycle disorders by causing anovulation or endometrial atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Primary ovarian insufficiency (premature ovarian failure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depletion of oocytes before age 40 years is called premature menopause or premature ovarian failure, but a better term is primary ovarian insufficiency, as this disorder is typically characterized by a waxing and waning clinical course. As a result, intermittent follicular development, estradiol production, menstrual bleeding, LH surges, and ovulation can occur between months of hypoestrogenemia. When primary ovarian insufficiency is complete, lack of ovarian function leads to estrogen deficiency, endometrial atrophy, and cessation of menstruation. Despite the intermittent ovarian function, conception is rare once a diagnosis of primary ovarian insufficiency has been made. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of the negative feedback effect of estradiol and inhibin on the hypothalamus and pituitary results in high serum FSH concentrations, which clearly distinguishes ovarian insufficiency from hypothalamic amenorrhea (in which serum FSH concentrations are low or normal). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link&amp;anchor=H171787387#H171787387\">",
"     \"Clinical manifestations and diagnosis of menopause\", section on 'Menstrual cycle and endocrine changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary ovarian insufficiency may be due to loss of an X chromosome (Turner syndrome), the fragile X premutation, autoimmune ovarian destruction, or most commonly, unknown causes. Radiation therapy or chemotherapy with alkylating agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may also result in premature ovarian failure. The approach to diagnosis and evaluation of primary ovarian insufficiency is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=see_link\">",
"     \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Uterine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asherman's syndrome is the only uterine cause of secondary amenorrhea. This syndrome results from acquired scarring of the endometrial lining, usually secondary to postpartum hemorrhage or endometrial infection followed by instrumentation such as a dilatation and curettage. This abnormality prevents the normal build-up and shedding of endometrial cells, leading to very light or absent menses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link&amp;anchor=H2#H2\">",
"     \"Intrauterine adhesions\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asherman's syndrome should be suspected in a woman with secondary amenorrhea and a history of a uterine infection or dilatation and curettage for an obstetrical complication. The diagnosis is suggested by the absence of a normal uterine stripe on pelvic ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/28\">",
"     28",
"    </a>",
"    ], and may be confirmed by the absence of withdrawal bleeding after administration of estrogen and then progestin for several weeks. The presence of Asherman&rsquo;s syndrome can be verified by hysteroscopic evaluation of the endometrium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link&amp;anchor=H4#H4\">",
"     \"Intrauterine adhesions\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once pregnancy and Asherman's syndrome have been excluded, all of the remaining causes of amenorrhea are associated with anovulation due to hypothalamic, pituitary, or ovarian disorders. Sequential hormonal changes that naturally occur are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .) Determining the site of the defect is important because it determines the appropriate therapeutic regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Step 1: Rule out pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pregnancy test is recommended as a first step in evaluating any woman with secondary amenorrhea. Measurement of serum beta subunit of hCG is the most sensitive test. Commercially available home kits for measurement of hCG in urine are improving, but the clinician who suspects pregnancy should order serum hCG measurement, even if the woman had a negative home test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Step 2: History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman should be questioned about any past medical history, risk factors, or symptoms that might suggest any of the major causes of secondary amenorrhea or oligomenorrhea (",
"    <a class=\"graphic graphic_table graphicRef59801 \" href=\"mobipreview.htm?1/19/1340\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lately, has there been stress, change in weight, diet or exercise habits, or illness that might result in hypothalamic amenorrhea? (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Functional hypothalamic amenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Is the woman taking any drugs that might cause or be associated with amenorrhea? The drug may be taken for a systemic illness that itself can cause hypothalamic amenorrhea. Newly initiated or discontinued oral contraceptives can be associated with several months of amenorrhea, as can androgenic drugs like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      or high-dose progestin. Other drugs cause amenorrhea by increasing serum prolactin concentrations, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      and antipsychotic drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Does the woman have acne, hirsutism, or deepening of the voice? (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Polycystic ovary syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Are there symptoms of other hypothalamic-pituitary disease, including headaches, visual field defects, fatigue, or polyuria and polydipsia? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link\">",
"       \"Causes, presentation, and evaluation of sellar masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Are there any symptoms of estrogen deficiency, including hot flashes, vaginal dryness, poor sleep, or decreased libido? These symptoms may be prominent in the early stages of ovarian insufficiency. In contrast, women with hypothalamic amenorrhea do",
"      <strong>",
"       not",
"      </strong>",
"      usually have these symptoms despite the presence of similarly low serum estrogen concentrations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=see_link\">",
"       \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=see_link\">",
"       \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there galactorrhea (suggestive of hyperprolactinemia), or hirsutism, acne, and a history of irregular menses (suggestive of hyperandrogenism)? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there a history of obstetrical catastrophe, severe bleeding, dilatation and curettage, or endometritis or other infection that might have caused",
"      <strong>",
"      </strong>",
"      scarring of the endometrial lining (Asherman's syndrome)? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"       \"Intrauterine adhesions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Step 3: Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination in women with secondary amenorrhea should include measurements of height and weight. A body mass index greater than 30",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    is observed in approximately 50 percent of women with PCOS. Women with a BMI less than 18.5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    may have functional hypothalamic amenorrhea due to an eating disorder, strenuous exercise, or a systemic illness associated with weight loss.",
"   </p>",
"   <p>",
"    The patient should be examined for hirsutism, acne, striae, acanthosis nigricans, vitiligo, and easy bruisability. Breasts should be examined for evidence of galactorrhea, and vulvovaginal exam should look for signs of estrogen deficiency. Parotid gland swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosion of dental enamel would suggest an eating disorder (bulimia nervosa). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=see_link&amp;anchor=H338476#H338476\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Common physical signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Step 4: Basic laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to measurement of serum hCG to rule out pregnancy, minimal laboratory testing should include measurements of serum prolactin, FSH, and TSH to test for hyperprolactinemia, ovarian failure, and thyroid disease. If there is clinical evidence of hyperandrogenism, serum total testosterone should be measured. In patients with evidence for hyperandrogenism, some clinicians also measure 17-hydroxyprogesterone at the initial visit to rule out nonclassic 21-hydroxylase deficiency, and dehydroepiandrosterone sulfate (DHEA-S) to look for an adrenal source of androgens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of premenopausal women with hirsutism\", section on 'Biochemical testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study performed in 127 women with adult-onset amenorrhea evaluated the frequency with which hormonal testing detected important abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/29\">",
"     29",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High serum FSH concentrations suggesting primary ovarian insufficiency (premature ovarian failure) &mdash; 10 percent",
"     </li>",
"     <li>",
"      Modest increase in serum prolactin concentrations &mdash; 7.5 percent",
"     </li>",
"     <li>",
"      Abnormal serum TSH &mdash; 2.5 percent; two women had hypothyroidism and one had hyperthyroidism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Step 5: Follow-up testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation depends upon the results of the initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Assessment of estrogen status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some assessment of estrogen status is typically done, in some cases to help with interpreting the FSH values, and in others to help guide therapy (eg, hypoestrogenic patients need estrogen therapy for prevention of bone loss, while those making estrogen need endometrial protection).",
"   </p>",
"   <p>",
"    Estrogen status can be assessed with a progestin withdrawal test, measurement of endometrial thickness on ultrasound, or a serum estradiol. There are no data to suggest the best approach. However, in women with either early ovarian failure or hypothalamic amenorrhea (during recovery), serum estradiol concentrations may be variable and may not reflect exposure to estradiol over weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     High serum prolactin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolactin secretion can be transiently increased by stress or eating. As a result, we recommend that serum prolactin be measured at least twice before pituitary MRI is ordered, particularly in those women with small elevations (&lt;50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;50",
"    <span class=\"nowrap\">",
"     mcg/L]).",
"    </span>",
"    All of these women should be screened for thyroid disease because hypothyroidism can cause hyperprolactinemia.",
"   </p>",
"   <p>",
"    All women with high serum prolactin values should undergo pituitary MRI unless a very clear explanation is found for the elevation (eg, underlying hypothyroidism or antipsychotic drug use). The goal of imaging is to evaluate the possibility of a hypothalamic or pituitary lesion. In the case of a lactotroph adenoma, the image will allow determination of whether it is a microadenoma or a macroadenoma (&le;1 or &gt;1 cm, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\", section on 'Laboratory/imaging tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     High serum FSH concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high serum FSH concentration indicates primary ovarian insufficiency (premature ovarian failure). It should be kept in mind, however, that intermittent follicle development does occur in ovarian failure, resulting in transient normalization of serum FSH concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A karyotype should then be considered to look for Turner syndrome (including mosaicism). The karyotype may demonstrate complete or partial deletion of the X chromosome, and it provides a precise diagnosis for many women. More importantly, a karyotype will help rule out the presence of any Y chromosome material, which, as noted above, makes gonadectomy mandatory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-adrenal antibodies and a fragile X premutation test are also recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Normal or low serum FSH concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum FSH concentration that is low or \"normal\" is inappropriately low in the presence of a low serum estradiol concentration and indicates secondary (hypogonadotropic) hypogonadism. This constellation is one of the most common outcomes of laboratory testing in women with amenorrhea. Women with hypothalamic amenorrhea have normal to low serum FSH values, with FSH typically higher than LH (if LH is measured).",
"   </p>",
"   <p>",
"    MRI of the sella region is indicated in all women without a clear explanation for hypogonadotropic hypogonadism and in most women who have normal laboratory findings and symptoms such as visual field defects, headaches, or other signs of hypothalamic-pituitary dysfunction. In contrast, no further testing is required if the onset of amenorrhea occurred lately or is easily explained and there are no symptoms suggestive of other disease.",
"   </p>",
"   <p>",
"    Other specific tests may be done, depending upon the clinical history. As examples, high serum transferrin saturation may indicate hemochromatosis, high serum angiotensin-converting enzyme values sarcoidosis, and high fasting blood glucose or hemoglobin A1c values diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Normal labs and history of uterine instrumentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for Asherman's syndrome (intrauterine adhesions) should be performed. Many clinicians start with a progestin challenge (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    10 mg for 10 days). If withdrawal bleeding occurs, an outflow tract disorder has been ruled out.",
"   </p>",
"   <p>",
"    If bleeding does not occur, estrogen and progestin may be administered. The endometrium may be primed with oral conjugated estrogens 0.625",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or its equivalent (oral estradiol 1",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    transdermal estradiol 0.05 mg) for 35 days. A progestin is then added from days 26 to 35 (typically medroxyprogesterone 10",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Failure to bleed upon cessation of this therapy strongly suggests endometrial scarring. In this situation, a hysterosalpingogram or direct visualization of the endometrial cavity with a hysteroscope can confirm the diagnosis of intrauterine adhesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     High serum androgen concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the clinical picture, a high serum androgen value may be consistent with the diagnosis of PCOS or may raise the question of an androgen-secreting tumor of the ovary or adrenal gland. Tumors are typically associated with the rapid onset of virilizing symptoms and, in some cases, with glucocorticoid excess. Most clinicians initiate evaluation for a tumor if the serum concentration of testosterone is greater than 150 to 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (5.2 to 6.9",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or that of DHEA-S is greater than 700",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (18.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of premenopausal women with hirsutism\", section on 'Biochemical testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of women with secondary amenorrhea should be directed at correcting the underlying pathology, if possible; helping the woman to achieve fertility, if desired; and medical treatment to prevent complications of the disease process (eg, estrogen replacement to prevent osteoporosis). A brief summary of treatment options is presented here:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195634\">",
"    <span class=\"h2\">",
"     Hypothalamic amenorrhea",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437270\">",
"    <span class=\"h3\">",
"     Lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many athletic women, simply explaining the need for adequate caloric intake to match energy expenditure results in increased caloric intake or reduced exercise, followed by resumption of menses. Nonathletic women who are underweight or who appear to have nutritional deficiencies should have nutritional counseling and can be referred to a multidisciplinary team specializing in the assessment and treatment of individuals with eating disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437278\">",
"    <span class=\"h3\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive behavioral therapy may be effective for restoring ovulatory cycles in some women. In one 20-week study, 16 women with functional hypothalamic amenorrhea were randomly assigned to receive cognitive behavioral therapy (CBT; 16 individual sessions with a clinician over the 20 weeks, focusing on healthy eating patterns and modifying maladaptive attitudes towards eating and weight) or observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/30\">",
"     30",
"    </a>",
"    ]. Six of eight women in the CBT arm resumed ovulatory cycles compared with two of eight in the observation group. Although this study was small, it suggests that CBT may be a reasonable intervention for women with functional hypothalamic amenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21437295\">",
"    <span class=\"h3\">",
"     Leptin administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, women with hypothalamic amenorrhea (HA) have relative leptin deficiency. In the pilot study, subcutaneous leptin appeared to improve the HA-associated abnormalities of the reproductive, thyroid, and growth hormone axes, as well as markers of bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H172207980\">",
"     'Role of leptin deficiency'",
"    </a>",
"    above.) Similar results were seen in a follow-up 36-week randomized trial of recombinant leptin therapy among 19 women with hypothalamic amenorrhea (10 and 9 in treatment and placebo groups, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/31\">",
"     31",
"    </a>",
"    ]. No change in bone mineral density was seen, but the duration of trial was likely too short to see changes. Menses developed in 7 of 10 and two of nine in the treatment and placebo groups, respectively. Ovulatory cycles occurred only in the treatment group (four of the seven who menstruated).",
"    <br/>",
"    <br/>",
"    Adverse effects included injection site reactions and antileptin antibodies that were non-neutralizing and did not interfere with efficacy. Weight loss occurred initially in some patients receiving leptin, but stabilized when doses were decreased. However, both total body fat mass and the percentage of body fat decreased (primarily in the first 24 weeks) with leptin compared to placebo. Both weight loss and loss of body fat would be unacceptable side effects in women with HA, who already have nutritional and energy deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1082646058\">",
"    <span class=\"h3\">",
"     Management of low bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of estrogen therapy on bone and the approach to women with exercise-associated amenorrhea are discussed separately. An overview of low bone density is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link&amp;anchor=H17#H17\">",
"     \"Amenorrhea and infertility associated with exercise\", section on 'Bone density'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leptin therapy is experimental; additional data are required to better determine its effects on the reproductive axis, bone, and other endocrine systems, as well as to establish its safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195642\">",
"    <span class=\"h2\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with amenorrhea due to hyperprolactinemia depends upon the cause of the hyperprolactinemia and the patient&rsquo;s goals (eg, pursuing fertility or not). This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195650\">",
"    <span class=\"h2\">",
"     Primary ovarian insufficiency (premature ovarian failure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with primary ovarian insufficiency should receive estrogen therapy for prevention of bone loss. This can be either an oral contraceptive (if the patient is having intermittent ovarian function and does not wish to become pregnant), or replacement doses of estrogen and progestin. Regimens for the latter are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195658\">",
"    <span class=\"h2\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperandrogenism is directed toward achieving the woman's goal (eg, relief of hirsutism, resumption of menses, fertility) and preventing the long-term consequences of PCOS (eg, endometrial hyperplasia, obesity, and metabolic defects). For women with PCOS, the type of therapy depends upon whether fertility is desired. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4215336\">",
"    <span class=\"h2\">",
"     Intrauterine adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of Asherman&rsquo;s syndrome consists of hysteroscopic lysis of adhesions followed by long-term estrogen administration to stimulate regrowth of endometrial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34697/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=see_link\">",
"       \"Patient information: Absent or irregular periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=see_link\">",
"       \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180195688\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary amenorrhea is characterized by the absence of menses for more than three cycles or six months in women who previously had menses. A step-wise approach to the history, physical examination, and laboratory testing usually results in a specific diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy is a common cause of secondary amenorrhea and should be excluded based on a sensitive pregnancy test (hCG). (See",
"      <a class=\"local\" href=\"#H180195280\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A common hypothalamic cause of secondary amenorrhea is functional hypothalamic amenorrhea. This condition may be associated with excessive exercise, eating disorders, systemic illnesses, or psychological stress. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Functional hypothalamic amenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common pituitary cause of secondary amenorrhea is hyperprolactinemia, which may be caused by a pituitary tumor, medications, or hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hyperprolactinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycystic ovary syndrome and primary ovarian insufficiency (the current term for premature ovarian failure) are common ovarian causes of secondary amenorrhea. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Polycystic ovary syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Primary ovarian insufficiency (premature ovarian failure)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common uterine disease that causes secondary amenorrhea is endometrial scarring (Asherman&rsquo;s syndrome), which may occur following uterine surgical procedures such as a curettage. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Uterine disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment depends upon the cause of the amenorrhea and the patient&rsquo;s goals (eg, fertility, cosmetic concerns, etc). Detailed discussions of treatment options for each disorder are found elsewhere. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/1\">",
"      Reindollar RH, Novak M, Tho SP, McDonough PG. Adult-onset amenorrhea: a study of 262 patients. Am J Obstet Gynecol 1986; 155:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/2\">",
"      Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2006; 86:S148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/3\">",
"      de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/4\">",
"      Crowley WF Jr, Jameson JL. Clinical counterpoint: gonadotropin-releasing hormone deficiency: perspectives from clinical investigation. Endocr Rev 1992; 13:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/5\">",
"      Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med 2010; 363:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/6\">",
"      Santoro N, Filicori M, Crowley WF Jr. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev 1986; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/7\">",
"      Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab 1999; 84:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/8\">",
"      Constantini NW, Warren MP. Menstrual dysfunction in swimmers: a distinct entity. J Clin Endocrinol Metab 1995; 80:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/9\">",
"      Warren MP. Clinical review 40: Amenorrhea in endurance runners. J Clin Endocrinol Metab 1992; 75:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/10\">",
"      Warren MP, Brooks-Gunn J, Fox RP, et al. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab 2002; 87:3162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/11\">",
"      Couzinet B, Young J, Brailly S, et al. Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clin Endocrinol (Oxf) 1999; 50:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/12\">",
"      Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998; 83:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/13\">",
"      Warren MP, Voussoughian F, Geer EB, et al. Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. J Clin Endocrinol Metab 1999; 84:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/14\">",
"      Miller KK, Grinspoon S, Gleysteen S, et al. Preservation of neuroendocrine control of reproductive function despite severe undernutrition. J Clin Endocrinol Metab 2004; 89:4434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/15\">",
"      Berga SL, Daniels TL, Giles DE. Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. Fertil Steril 1997; 67:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/16\">",
"      Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/17\">",
"      Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 2011; 364:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/18\">",
"      Perkins RB, Hall JE, Martin KA. Aetiology, previous menstrual function and patterns of neuro-endocrine disturbance as prognostic indicators in hypothalamic amenorrhoea. Hum Reprod 2001; 16:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/19\">",
"      Falsetti L, Gambera A, Barbetti L, Specchia C. Long-term follow-up of functional hypothalamic amenorrhea and prognostic factors. J Clin Endocrinol Metab 2002; 87:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/20\">",
"      Molteni N, Bardella MT, Bianchi PA. Obstetric and gynecological problems in women with untreated celiac sprue. J Clin Gastroenterol 1990; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/21\">",
"      Kooy A, de Greef WJ, Vreeburg JT, et al. Evidence for the involvement of corticotropin-releasing factor in the inhibition of gonadotropin release induced by hyperprolactinemia. Neuroendocrinology 1990; 51:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/22\">",
"      Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/23\">",
"      Grubb MR, Chakeres D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987; 83:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/24\">",
"      Kakuno Y, Amino N, Kanoh M, et al. Menstrual disturbances in various thyroid diseases. Endocr J 2010; 57:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/25\">",
"      Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/26\">",
"      Burgers JA, Fong SL, Louwers YV, et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference? J Clin Endocrinol Metab 2010; 95:E485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/27\">",
"      Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/28\">",
"      Schlaff WD, Hurst BS. Preoperative sonographic measurement of endometrial pattern predicts outcome of surgical repair in patients with severe Asherman's syndrome. Fertil Steril 1995; 63:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/29\">",
"      Laufer MR, Floor AE, Parsons KE, et al. Hormone testing in women with adult-onset amenorrhea. Gynecol Obstet Invest 1995; 40:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/30\">",
"      Berga SL, Marcus MD, Loucks TL, et al. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertil Steril 2003; 80:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/31\">",
"      Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A 2011; 108:6585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34697/abstract/32\">",
"      Broome JD, Vancaillie TG. Fluoroscopically guided hysteroscopic division of adhesions in severe Asherman syndrome. Obstet Gynecol 1999; 93:1041.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7402 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-A3347AB727-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34697=[""].join("\n");
var outline_f33_56_34697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H180195688\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180195280\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypothalamic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H132363\">",
"      - Congenital GnRH deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Functional hypothalamic amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H132066\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H172207980\">",
"      Role of leptin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H132415\">",
"      Genetic basis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H180195287\">",
"      Recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Infiltrative lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H464655914\">",
"      - Systemic illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H464655922\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pituitary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other sellar masses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other diseases of the pituitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ovarian disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Uterine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Step 1: Rule out pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Step 2: History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Step 3: Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Step 4: Basic laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Step 5: Follow-up testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Assessment of estrogen status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - High serum prolactin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - High serum FSH concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Normal or low serum FSH concentrations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Normal labs and history of uterine instrumentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - High serum androgen concentrations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180195634\">",
"      Hypothalamic amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437270\">",
"      - Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437278\">",
"      - Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21437295\">",
"      - Leptin administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1082646058\">",
"      - Management of low bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180195642\">",
"      Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180195650\">",
"      Primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180195658\">",
"      Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4215336\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180195688\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7402\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7402|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/19/1340\" title=\"table 1\">",
"      Causes of amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/25/26012\" title=\"table 2\">",
"      HPO axis and amenorrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=related_link\">",
"      Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34698="Treatment of acute decompensated heart failure: Components of therapy";
var content_f33_56_34698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute decompensated heart failure: Components of therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/56/34698/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/56/34698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of acute respiratory distress. The clinical syndrome is characterized by the development of dyspnea, generally associated with rapid accumulation of fluid within the lung's interstitial and alveolar spaces, which is the result of acutely elevated cardiac filling pressures (cardiogenic pulmonary edema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/1\">",
"     1",
"    </a>",
"    ]. ADHF can also present as elevated left ventricular filling pressures and dyspnea without pulmonary edema.",
"   </p>",
"   <p>",
"    ADHF is most commonly due to left ventricular (LV) systolic or diastolic dysfunction, with or without additional cardiac pathology, such as coronary artery disease or valve abnormalities. However, a variety of conditions or events can cause cardiogenic pulmonary edema due to an elevated pulmonary capillary wedge pressure in the absence of heart disease, including primary fluid overload (eg, due to blood transfusion), severe hypertension, particularly renovascular hypertension, and severe renal disease.",
"   </p>",
"   <p>",
"    The components of therapy of ADHF in patients with and without acute myocardial infarction (MI) will be reviewed here. A table to assist with emergency management of ADHF is provided (",
"    <a class=\"graphic graphic_table graphicRef75041 \" href=\"mobipreview.htm?20/58/21421\">",
"     table 1",
"    </a>",
"    ). General considerations for treatment of ADHF and the pathophysiology and evaluation of patients with ADHF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of ADHF and cardiogenic shock in the setting of acute coronary syndrome is discussed separately. Management of right ventricular MI, which typically presents with hypotension and clear lungs, is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with acute dyspnea from ADHF should be rapidly assessed and stabilized. A table to assist with emergency management of ADHF is provided (",
"    <a class=\"graphic graphic_table graphicRef75041 \" href=\"mobipreview.htm?20/58/21421\">",
"     table 1",
"    </a>",
"    ). Stabilization measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway assessment to assure adequate oxygenation and ventilation, including continuous pulse oximetry",
"     </li>",
"     <li>",
"      Vital signs assessment with attention to hypotension or hypertension",
"     </li>",
"     <li>",
"      Continuous cardiac monitoring",
"     </li>",
"     <li>",
"      Intravenous access",
"     </li>",
"     <li>",
"      Seated posture",
"     </li>",
"     <li>",
"      Diuretic therapy",
"     </li>",
"     <li>",
"      Vasodilator therapy",
"     </li>",
"     <li>",
"      Urine output monitoring (perhaps with urethral catheter placement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following airway and oxygenation assessment, initial stabilization includes the initiation of therapies aimed at the rapid correction of hemodynamic and intravascular volume abnormalities. The mainstay of therapy for these abnormalities in the acute setting is vasodilator and diuretic therapy. The aggressiveness of each depends on the patient's hemodynamic and volume status. Patients with flash pulmonary edema due to hypertension, for instance, require aggressive vasodilatory therapy. Patients with normotension and volume overload best respond to a combination of diuretic therapy and vasodilators. Patients with hypotension and intravascular overload cannot tolerate vasodilators, and may respond either to diuretics alone or in combination with inotropes. It is important to tailor the therapy to the individual patient. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Inotropic agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Mechanical cardiac assistance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Supplemental oxygen and assisted ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen therapy and assisted ventilation should be provided as needed. The 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend oxygen therapy to relieve symptoms related to hypoxemia. The 2010 HFSA guidelines note that routine administration of supplemental oxygen in the absence of hypoxia is NOT recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients requiring supplemental oxygen, we suggest initial therapies in the following order:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-rebreather face mask delivering high-flow percent oxygen.",
"     </li>",
"     <li>",
"      If respiratory distress, respiratory acidosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoxia persist, we suggest noninvasive positive pressure ventilation (NPPV) as the preferred initial modality of assisted ventilation as long as the patient does not have a contraindication (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is supported by evidence from meta-analyses and randomized trials in patients with cardiogenic pulmonary edema indicating that NPPV decreases the need for intubation and improves respiratory parameters, such as dyspnea, hypercapnia, acidosis, and heart rate. NPPV may be particularly beneficial in patients with hypercapnia. These issues and conflicting data on a possible impact on mortality are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H16#H16\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Cardiogenic pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with respiratory failure who fail NPPV, or do not tolerate or have contraindications to NPPV (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 2",
"      </a>",
"      ) should be intubated for conventional mechanical ventilation. In such patients, positive end-expiratory pressure is often useful to improve oxygenation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"       \"Overview of mechanical ventilation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=see_link\">",
"       \"Positive end-expiratory pressure (PEEP)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once initial therapy has begun, oxygen supplementation can be titrated in order to keep the patient comfortable and arterial oxygen saturation above 90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF are usually volume overloaded. Even in the less common situation in which cardiogenic pulmonary edema develops without significant volume overload (eg, with hypertensive emergency, acute aortic or mitral valvular insufficiency), fluid removal with intravenous diuretics can relieve symptoms and improve oxygenation.",
"   </p>",
"   <p>",
"    Limited clinical trial data have shown a mortality benefit from diuretic therapy in patients with chronic HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H31397796#H31397796\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Efficacy and safety'",
"    </a>",
"    .) Although the safety and efficacy of diuretics to treat ADHF have not been established in randomized trials, extensive observational experience has demonstrated that they effectively relieve congestive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ADHF and evidence of volume overload, regardless of etiology, should be treated with intravenous diuretics as part of their initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. Rare exceptions include patients with severe hypotension or cardiogenic shock. In such cases, the underlying cause for hemodynamic instability should be sought and the patient may require hemodynamic and mechanical ventilatory support. Patients with aortic stenosis with volume overload should be diuresed with caution. As noted in the 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines, patients admitted with significant fluid overload should receive diuretic therapy without delay in the emergency department or outpatient clinic as early intervention may produce better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous rather than oral administration is recommended because of greater and more consistent drug bioavailability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diuretic dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common initial intravenous doses of loop diuretics in patients with normal renal function include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       Furosemide",
"      </a>",
"      &mdash; 40 mg intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       Bumetanide",
"      </a>",
"      &mdash; 1 mg intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       Torsemide",
"      </a>",
"      &mdash; 10 to 20 mg intravenously",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diuretic dosing should be individualized and titrated according to response and patient status. Patients who are treated with loop diuretics chronically are usually treated with a higher dose in the acute setting; the intravenous dose should be equal to or greater than (eg, 2.5 times) their maintenance oral dose (eg, an intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    dose of 40 to 100 mg for a patient who had been taking 40 mg orally per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ]. In the DOSE trial of intravenous furosemide in patients with ADHF, there was an almost significant trend toward greater improvement in patients&rsquo; global assessment of symptoms in the high dose (2.5 times the patients&rsquo; prior dose) group compared to the low dose (equal the prior dose) group as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peak diuresis typically occurs 30 minutes after administration. Most patients will require additional diuresis through the course of their care. Diuretic administration two or more times per day may be necessary.",
"   </p>",
"   <p>",
"    No single intravenous dosing regimen (bolus versus continuous infusion; high dose versus lower dose) has been shown to be superior to others as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of seven trials with a total of 221 patients with ADHF suggested that continuous infusion of a loop diuretic slightly increased the urine output (by a mean of 271",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      compared to intermittent bolus injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/7\">",
"       7",
"      </a>",
"      ]. Less tinnitus and hearing loss occurred with continuous infusion. However, the studies were small and heterogeneous and the results were largely driven by the largest trial (107 patients) in which hypertonic saline was administered only to the patients receiving continuous infusion of diuretic.",
"     </li>",
"     <li>",
"      The best data come from the DOSE trial, published after the meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/6\">",
"       6",
"      </a>",
"      ]. The trial randomly assigned 308 patients to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      administered intravenously via either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient&rsquo;s previous oral dose) or a high dose (2.5 times the previous oral dose). The efficacy endpoint was the patients&rsquo; global assessment of symptoms over the course of 72 hours and the safety endpoint was change in serum creatinine from baseline to 72 hours. Worsening renal function was defined as increase in the serum creatinine &gt;0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&gt;26.5",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      at any time during the 72 hours after randomization.",
"      <br/>",
"      <br/>",
"      The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no significant difference in efficacy or safety endpoints for bolus versus continuous infusion. Patients assigned to intravenous bolus therapy were more likely to require a dose increase at 48 hours; as a result, the total dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      over 72 hours was higher in the bolus group compared with the continuous infusion group, a difference that was almost statistically different (592 versus 480 mg, p = 0.06).",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , compared with low-dose furosemide, produced greater net fluid loss, weight loss, and relief from dyspnea but also more frequent transient worsening of renal function (23 versus 14 percent). There was an almost significant trend toward greater improvement in patients&rsquo; global assessment of symptoms in the high-dose group (p = 0.06); the mean change in the serum creatinine was less than 0.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (9",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the available data suggest that intravenous continuous infusion and bolus loop diuretic therapy have similar efficacy in patients with ADHF.",
"   </p>",
"   <p>",
"    Later transition from intravenous to oral diuretics should be made with careful attention to HF status, supine and upright hypotension, renal function and electrolytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume status, evidence of congestion, daily weights, intake, and output should be continually reassessed. Monitoring should also include watching for and guarding against side effects (including worsening renal function, electrolyte abnormalities (with associated arrhythmia risk), and symptomatic hypotension). Diuretic therapy can also precipitate attacks of gout. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum potassium and magnesium levels should be monitored at least daily, and more frequent monitoring is indicated when diuresis is rapid. Severe muscle cramps may occur with overly rapid diuresis and should be treated with potassium repletion if indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hemodynamic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;By reducing intravascular volume, diuresis will eventually lower central venous and pulmonary capillary wedge pressures. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    and possibly other loop diuretics also have an initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    -like effect in acute pulmonary edema, causing venodilation that can decrease pulmonary congestion prior to the onset of diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/8\">",
"     8",
"    </a>",
"    ]. This effect appears to be mediated by enhanced release of prostaglandins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Venodilatory effect in acute pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reductions in right and left heart filling pressures with diuresis are frequently associated with augmented forward stroke volume and cardiac output related to decreases in functional tricuspid and mitral regurgitation and reduction in right ventricular volume with relief of left ventricular compression and improved left ventricular distensibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, during diuresis some patients experience symptomatic hypotension with decreasing cardiac output and systemic blood pressure due to a lag in reequilibration of intravascular volume via movement of fluid from the interstitial space. Patients with HF with preserved LV ejection fraction (LVEF) or restrictive physiology may be more sensitive to diuresis-induced reductions in preload. Diuretics may enhance the hypotensive effects of ACE inhibitor or angiotensin receptor blocker (ARB) therapy even when volume overload persists. Careful monitoring during diuresis is required to prevent adverse hemodynamic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effects on renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood urea nitrogen (BUN) and serum creatinine often rise during diuretic treatment of ADHF and careful monitoring is recommended. In the absence of other causes for an elevated BUN, a disproportionate rise in BUN relative to serum creatinine",
"    <span class=\"nowrap\">",
"     (BUN/serum",
"    </span>",
"    creatinine ratio &gt;20:1) suggests a prerenal state with increased passive reabsorption of urea. An initial rise in BUN may be accompanied by a stable serum creatinine, reflecting preserved glomerular filtration rate (GFR). Further elevations in BUN along with a rise in serum creatinine are likely if diuresis is continued in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Blood urea nitrogen/serum creatinine ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An otherwise unexplained rise in serum creatinine, which reflects a reduction in GFR, may be a marker of reduced perfusion to the kidney and other organs. Patients in whom this occurs before euvolemic status is achieved have a worse prognosis. Nevertheless, fluid removal may still be required to treat signs and symptoms of congestion, particularly pulmonary edema. On the other hand, a stable serum creatinine suggests that perfusion to the kidneys (and therefore to other organs) is being well maintained and that the diuresis can be continued if the patient is still edematous. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H2022685#H2022685\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Reduced renal perfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=see_link&amp;anchor=H28486497#H28486497\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\", section on 'Change in GFR during therapy for HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changes in cardiac output and the consequent changes in renal perfusion is not the only determinant of changes in GFR in patients with HF. Among patients with an elevated central venous pressure, the associated increase in renal venous pressure can reduce the GFR, while lowering venous pressure with diuretics and other therapies might therefore increase the GFR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for management of patients with ADHF with elevated or rising BUN",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum creatinine include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other potential causes of kidney injury (eg, use of nephrotoxic medications, urinary obstruction) should be evaluated and addressed.",
"     </li>",
"     <li>",
"      Patients with severe symptoms or signs of congestion, particularly pulmonary edema, require continued fluid removal independent of changes in GFR. In the presence of elevated central venous pressure, renal function may improve with diuresis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H2022699#H2022699\">",
"       \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Increased renal venous pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the BUN rises and the serum creatinine is stable or increases minimally, and the patient is still fluid overloaded, the diuresis can be continued to achieve the goal of eliminating clinical evidence of fluid retention with careful monitoring of renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H4016559#H4016559\">",
"       \"Use of diuretics in patients with heart failure\", section on 'Goals of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If increases in serum creatinine appear to reflect intravascular volume depletion, then reduction in or temporary discontinuation of diuretic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      therapy should be considered. Adjunctive inotropic therapy may be required. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Inotropic agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If substantial congestion persists and adequate diuresis cannot be achieved, then ultrafiltration or dialysis should be considered. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ultrafiltration'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inadequate response to diuretic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with ADHF do not respond adequately to initial loop diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. These patients should be re-evaluated for congestion. The approach to patients with refractory edema is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium intake should be restricted to a limit of &lt;2 g daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"       2",
"      </a>",
"      ]. Water restriction is also warranted in patients with hyponatremia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Sodium and fluid restriction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Doubling the diuretic dose until diuresis ensues or the maximum recommended dose is reached. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link&amp;anchor=H2#H2\">",
"       \"Loop diuretics: Maximum effective dose and major side effects\", section on 'Maximum effective dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Addition of a second diuretic to potentiate the effects of the loop diuretic. The HFSA and",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines recommend oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"       metolazone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/2/35878?source=see_link\">",
"       chlorothiazide",
"      </a>",
"      as the second diuretic agent to add when diuretic response is inadequate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2,4\">",
"       2,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/2/35878?source=see_link\">",
"       Chlorothiazide",
"      </a>",
"      is the only thiazide diuretic that can be given intravenously (500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      However, the availability of this preparation may be limited. An oral thiazide, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      (25 to 50 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"       metolazone",
"      </a>",
"      (which has the advantage of once daily dosing) is an alternative for acute therapy and can be given chronically. Although it has been suggested that metolazone is the thiazide of choice in refractory patients with advanced renal failure (GFR below 20",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      there is at present no convincing evidence that metolazone has unique efficacy among the thiazides when comparable doses are given. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of refractory edema in adults\", section on 'Enhanced tubular sodium reabsorption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Addition of an aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) is recommended in selected patients with systolic HF to improve survival. In addition, the associated reduction in collecting tubule sodium reabsorption and potassium secretion can both enhance the diuresis and minimize the degree of potassium wasting. Thus, if not already being given, it is reasonable to initiate aldosterone antagonist therapy",
"      <strong>",
"       prior",
"      </strong>",
"      to the addition of a thiazide diuretic in patients with a low or low-normal serum potassium on loop diuretic therapy alone. Aldosterone antagonist therapy should be continued following hospital discharge only in patients who can be carefully monitored for hyperkalemia. When given for diuresis or potassium sparing effects, a higher dose (up to 100 mg daily) than the usual heart failure dose may be needed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of refractory edema in adults\", section on 'Enhanced tubular sodium reabsorption'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27389179\">",
"       'Aldosterone antagonist therapy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      If these modalities are not sufficiently effective, ultrafiltration may be considered. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ultrafiltration'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sodium and fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary sodium restriction is an important component of therapy to restore euvolemia, and greater restriction may be feasible in hospital than in the outpatient setting. The Heart Failure Society of America (HFSA) guidelines on acute decompensated heart failure (ADHF) recommend a low-sodium diet (2 g daily) and consideration of stricter sodium restriction in patients with recurrent or refractory volume overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia is common among HF patients and the degree of reduction in serum sodium parallels the severity of the heart failure. As a result, a low serum sodium is an adverse prognostic indicator. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most HF patients with hyponatremia have volume overload, rather than volume depletion. The HFSA guidelines recommend fluid restriction (&lt;2",
"    <span class=\"nowrap\">",
"     L/day)",
"    </span>",
"    in HF patients with moderate hyponatremia (serum sodium &lt;130",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and volume overload and suggest that fluid restriction should be considered to assist in treatment of fluid overload in other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]. Stricter fluid restriction may be considered in patients with severe (serum sodium &lt;125",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    or worsening hyponatremia, although patient tolerance of strict fluid restriction may be limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link&amp;anchor=H5#H5\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vasodilator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without hypotension with severely symptomatic fluid overload, vasodilators such as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    can be beneficial when added to diuretics or in those who do not respond to diuretics alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with systemic hypertension may require more aggressive vasodilator therapy (eg, up-titration of nitroglycerin) to assure more rapid reversal of dyspnea.",
"   </p>",
"   <p>",
"    The 2010 HFSA guidelines provide the following recommendations for use of vasodilators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous vasodilators (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ) and diuretics are recommended for rapid symptom relief in patients with acute pulmonary edema or severe hypertension.",
"     </li>",
"     <li>",
"      In the absence of symptomatic hypotension, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      may be considered as an addition to diuretic therapy for rapid improvement of congestive symptoms in patients admitted with ADHF.",
"     </li>",
"     <li>",
"      Frequent blood pressure monitoring is recommended with vasodilator agents. Dosage of these agents should be decreased if symptomatic hypotension develops. Once symptomatic hypotension is resolved, reintroduction and titration may be considered.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      may be considered in patients with ADHF and advanced HF who have persistent severe HF despite aggressive treatment with diuretics and standard oral therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates are the most commonly used vasodilators. In patients without symptomatic hypotension, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    added to diuretic therapy may contribute to rapid improvement in congestive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Nitroglycerin reduces LV filling pressure primarily via venodilation. At higher doses the drug variably lowers systemic afterload and increases stroke volume and cardiac output.",
"   </p>",
"   <p>",
"    The benefit of nitrate therapy was illustrated by a study in which 110 patients were randomly assigned to a combination of either high dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    plus low dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    or low dose isosorbide dinitrate plus high dose furosemide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients receiving the high dose isosorbide dinitrate and low dose furosemide combination had a significantly lower combined risk of myocardial infarction, requirement for mechanical ventilation or death than those treated with the high dose diuretic and low dose isosorbide regimen.",
"   </p>",
"   <p>",
"    Tachyphylaxis can occur within hours with administration of high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    and the strategy of nitrate-free interval used to reduce tolerance during chronic therapy could result in adverse hemodynamic effects in patients with ADHF. Potential adverse effects of nitroglycerin include hypotension and headache. Nitrate administration is contraindicated after use of PDE-5 inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual activity in patients with heart disease\", section on 'Adverse interaction with nitrates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with ADHF, we recommend intravenous rather than transdermal (ointment or patch) or oral nitrate administration for greater speed and reliability of delivery and ease of titration. An initial dose of 5 to 10",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is recommended with the dose increased in increments of 5 to 10",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    every 3 to 5 minutes as required and tolerated (dose range 10 to 200",
"    <span class=\"nowrap\">",
"     mcg/min).",
"    </span>",
"   </p>",
"   <p>",
"    Similar benefits have been described with high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, if hypotension occurs, the longer half-life of isosorbide dinitrate compared to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (four hours versus three to five minutes) is a major disadvantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nitroprusside",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    is a potent vasodilator with balanced venous and arteriolar effects producing rapid reduction in pulmonary capillary wedge pressure and increase in cardiac output. A need for pronounced afterload reduction is an indication for nitroprusside (initial dose 5 to 10",
"    <span class=\"nowrap\">",
"     mcg/min,",
"    </span>",
"    dose titrated up to every 5 minutes, dose range 5 to 400",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    as opposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/11\">",
"     11",
"    </a>",
"    ]. Examples of such settings include hypertensive emergency, acute aortic regurgitation, acute mitral regurgitation, or acute ventricular septal rupture. The dose is generally titrated to maintain a systolic blood pressure &gt;90 mmHg or mean arterial pressure &gt; 65 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug treatment of hypertensive emergencies\", section on 'Nitroprusside'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major limitation to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is its metabolism to cyanide. The accumulation of nitroprusside metabolites can lead to the development of cyanide, or rarely thiocyanate, toxicity which may be fatal. Doses above 400",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    generally do not provide greater benefit and may increase the risk of thiocyanate toxicity. Nitroprusside administration requires close and continuous blood pressure monitoring, and may cause reflex tachycardia. Another potential risk is rebound vasoconstriction upon discontinuation of nitroprusside [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, the use of nitroprusside is limited to selected patients, usually for durations of less than 24 to 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nesiritide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    in patients with acute HF, ASCEND-HF, found that nesiritide increased rates of hypotension, did not alter rates of death or rehospitalization at 30 days, and showed a borderline significant trend toward reducing dyspnea. There was no change in risk of worsening renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients hospitalized with acute heart failure (HF), we recommend",
"    <strong>",
"     not",
"    </strong>",
"    treating with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    . In carefully selected patients with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of nesiritide may be helpful as an alternative to other vasodilator therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ). Nesiritide has a longer effective half-life than nitroglycerin or nitroprusside, so side effects such as hypotension may persist longer.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=see_link&amp;anchor=H7#H7\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\", section on 'Use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    is typically given as an initial intravenous bolus of 2",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    followed by a continuous infusion of 0.01",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute, with subsequent dose adjustment as necessary. Close monitoring of hemodynamics, urine output, and renal function are necessary for effective clinical use and safety.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADDITIONAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with HF due to systolic dysfunction, ACE inhibitors or angiotensin receptor blockers (ARBs) are a mainstay of chronic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with ADHF, the role of angiotensin inhibition depends upon whether the patient is already receiving such therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Continued therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the majority of patients with systolic dysfunction who have been treated with chronic ACE inhibitor or ARB therapy, maintenance oral therapy can be cautiously continued during an episode of ADHF in the absence of hemodynamic instability or contraindications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ]. These medications should be decreased or discontinued in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Acute renal failure",
"     </li>",
"     <li>",
"      Hyperkalemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With regard to hypotension, two additional points should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with chronic HF and severe left ventricular systolic dysfunction tolerate relatively low blood pressures (eg, systolic blood pressure 90 to 100 mmHg). Such patients often tolerate chronic ACE inhibitor or ARB therapy and may tolerate these drugs in the acute setting as well.",
"     </li>",
"     <li>",
"      Patients with acute pulmonary edema may initially be hypertensive due to high catecholamine levels during the early period of distress. With initial therapy, blood pressure may fall rapidly and patients may become relatively hypotensive, particularly if they are aggressively diuresed. Thus, long-acting drugs, such as ACE inhibitors and ARBs, should be administered with caution the first few hours of hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some have advocated early use of ACE inhibitor in patients with acute decompensated heart failure, we do not recommend this approach. There are limited data on the safety and efficacy of initiating new ACE inhibitor or ARB therapy in the early phase of therapy of ADHF (ie, the first 12 to 24 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major concerns with early therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ADHF may develop hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      worsening renal function during initial therapy. Determining the pathogenesis of such complications is more difficult if an ACE inhibitor or ARB has been given. Hypotension following administration of these agents may be prolonged given the long effective half-lives of these agents.",
"     </li>",
"     <li>",
"      The intravenous ACE inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/22/20839?source=see_link\">",
"       enalaprilat",
"      </a>",
"      may have deleterious effects in patients with an acute myocardial infarction, especially when complicated by HF or aggressive diuresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/22/20839?source=see_link\">",
"     enalaprilat",
"    </a>",
"    is contraindicated in acute myocardial infarction, and not generally recommended in other patients with acute heart failure, although potentially useful in certain situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Early initiation of oral ACE inhibitor therapy is also",
"    <strong>",
"     not",
"    </strong>",
"    recommended (except for those with acute infarction), and should be avoided in patients at high risk for hypotension (eg, low baseline blood pressure or hyponatremia, which is a marker for increased activation of the renin-angiotensin system and therefore increased dependence upon angiotensin II for blood pressure maintenance). In addition, the aggressive diuretic therapy typically given for acute pulmonary edema may increase sensitivity to ACE inhibition or angiotensin blockade, including risks of hypotension and renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is stable, chronic oral therapy with ACE inhibitor or ARB can be started. Initiation of these therapies known to improve outcomes is recommended in stable patients with systolic dysfunction prior to hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inotropic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous inotropic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    may be helpful in selected patients with severe LV systolic dysfunction and low output syndrome (diminished peripheral perfusion and end-organ dysfunction) for whom treatment may be limited by marginal systemic blood pressure or inadequate response to vasodilator and diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As recommended in the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update, for patients with evidence of hypotension associated with hypoperfusion AND obvious evidence of elevated cardiac filling pressures (eg, elevated jugular venous pressure or elevated pulmonary artery wedge pressure), intravenous inotropic or vasopressor drugs are recommended to maintain systemic perfusion and preserve end-organ function while more definitive treatment is considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the usefulness of intravenous inotropic drugs to maintain systemic perfusion and preserve end-organ performance is uncertain for patients with severe systolic dysfunction, low blood pressure and evidence of low cardiac output.",
"   </p>",
"   <p>",
"    Similarly, the 2010 HFSA guidelines for ADHF include the following recommendations for use of inotropes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous inotropes (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) may be considered to relieve symptoms and improve end-organ function in patients with advanced HF characterized by LV dilation, reduced LVEF, and diminished peripheral perfusion or end-organ dysfunction (low output syndrome), particularly if these patients have marginal systolic blood pressure (&lt;90 mmHg), have symptomatic hypotension despite adequate filling pressure, or are unresponsive to, or intolerant of, intravenous vasodilators.",
"     </li>",
"     <li>",
"      Intravenous inotropes may be considered in similar patients (ie, patients with depressed systolic function and marginal cardiac output) with evidence of fluid overload if they respond poorly to intravenous diuretics or manifest diminished or worsening renal function.",
"     </li>",
"     <li>",
"      When adjunctive therapy is needed in other patients with ADHF (eg, patients with preserved cardiac output), administration of vasodilators should be considered instead of intravenous inotropes.",
"     </li>",
"     <li>",
"      Intravenous inotropes are not recommended unless left heart filling pressures are known to be elevated or cardiac index is severely impaired based on direct measurement or clear clinical signs.",
"     </li>",
"     <li>",
"      Administration of intravenous inotropes (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) in the setting of ADHF should be accompanied by continuous or frequent blood pressure monitoring and continuous monitoring of cardiac rhythm.",
"     </li>",
"     <li>",
"      If symptomatic hypotension or worsening tachyarrhythmias develop during administration of these agents, discontinuation or dose reduction should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inotropes are not indicated for treatment of ADHF in the setting of preserved systolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern that inotropic agents may adversely impact outcomes in patients with ADHF with congestion without a low output state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Inotropic agents may increase heart rate and myocardial oxygen consumption and thus provoke ischemia and potentially damage hibernating but viable myocardium, particularly in patients with ischemic heart disease. In addition, inotropic agents can increase atrial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/19\">",
"     19",
"    </a>",
"    ] and ventricular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/21\">",
"     21",
"    </a>",
"    ] arrhythmias. Given these concerns, careful patient selection is required for inotrope use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link&amp;anchor=H4#H4\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\", section on 'Intravenous therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine use of inotropes in patients hospitalized for heart failure was found to be harmful in the OPTIME-CHF trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/19\">",
"     19",
"    </a>",
"    ]. In this trial, 949 patients admitted to the hospital with an acute exacerbation of chronic HF were randomly assigned to a 48 to 72 hour infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    or placebo. Milrinone therapy was associated with significant increases in hypotension requiring intervention and atrial arrhythmias, and with nonsignificant increases in mortality in-hospital (3.8 versus 2.3 percent) and at 60 days (10.3 versus 8.9 percent). This trial did not evaluate patients whose treating physicians felt could not be randomized, but demonstrates overall adverse effects in noncritical patients despite improved symptoms.",
"   </p>",
"   <p>",
"    The general role of inotropic agents in patients with heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link&amp;anchor=H4#H4\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\", section on 'Intravenous therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Specific agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 HFSA guidelines advised careful titration of either of the following inotropes when used in highly selected patients with ADHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       Milrinone",
"      </a>",
"      &mdash; Milrinone is a phosphodiesterase inhibitor that increases myocardial inotropy by inhibiting degradation of cyclic AMP. Other direct effects of milrinone include reducing systemic and pulmonary vascular resistance (via inhibition of peripheral phosphodiesterase) and improving left ventricular diastolic compliance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. These changes lead to an increase in cardiac index and decrease in left ventricular afterload and filling pressures. Patients should receive a loading dose of 50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      over 10 minutes, followed by a maintenance dose of 0.375 to a maximum of 0.750",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min. Dose adjustment is required in the presence of renal insufficiency, hypotension, or arrhythmias.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      &mdash; Dobutamine acts primarily on beta-1 adrenergic receptors, with minimal effects on beta-2 and alpha-1 receptors. The hemodynamic effects of dobutamine include increase in stroke volume, and cardiac output, and modest decreases in systemic vascular resistance and pulmonary capillary wedge pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The 2004",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      STEMI guidelines suggest using dobutamine in patients with hypotension who do not have clinical evidence of shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/16\">",
"       16",
"      </a>",
"      ]. It should be started at 2.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min and, if tolerated and needed, can be gradually increased to 15",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    does not act via beta receptors, its effects are not as diminished as those of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    by concomitant beta blocker therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link&amp;anchor=H28#H28\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Combination with dobutamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\", section on 'Inotropic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14168249\">",
"    <span class=\"h2\">",
"     Vasopressor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with ADHF and marked hypotension, vasopressor therapy can be used as a temporizing measure to preserve systemic blood pressure and end-organ perfusion, although at the cost of increasing afterload and decreasing cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. Vasopressor use should be limited to patients with persistent hypotension with symptoms or evidence of consequent end-organ hypoperfusion despite optimization of filling pressures and consideration of the use of inotropic agents. In this setting, invasive monitoring can be helpful to assess filling pressures and systemic vascular resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=see_link&amp;anchor=H7#H7\">",
"     \"Pulmonary artery catheterization: Indications and complications\", section on 'Indications'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Vasopressors used in this setting include norepinephrine, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    (&gt;5",
"    <span class=\"nowrap\">",
"     micrograms/kg/min),",
"    </span>",
"    and vasopressin and these should be carefully titrated to achieve adequate perfusion of vital organs. Dopamine and norepinephrine have beta inotropic as well as vasopressor activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers reduce mortality when used in the long-term management of such patients, but must be used cautiously in patients with decompensated HF with systolic dysfunction because of the potential to worsen acute HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, in patients with systolic dysfunction and ADHF, we approach the use of beta blockers in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients on chronic beta blocker therapy, if the degree of decompensation is mild without hypotension or evidence of hypoperfusion, continuation of beta blocker as tolerated is recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"       4",
"      </a>",
"      ]. Support for continuation of beta blocker therapy in this setting comes from retrospective analyses of patients enrolled in randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/27,28\">",
"       27,28",
"      </a>",
"      ] and reports from the OPTIMIZE-HF program and the Italian Survey on Acute Heart Failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Withdrawal of beta blocker therapy was associated with increased mortality as compared to continuation of such therapy. However, these retrospective analyses cannot definitively determine whether the discontinuation was the cause of the worse outcome. While the increase in mortality was only partially explained by greater clinical risk factors in the patients withdrawn from beta blocker therapy, such analyses cannot account for all factors. For more severely ill patients, halving of the dose of beta blockers or discontinuation may be necessary.",
"     </li>",
"     <li>",
"      For patients on chronic beta blocker therapy with moderate-to-severe decompensation or hypotension, we decrease or withhold beta blocker therapy during the early phase of treatment. In patients requiring inotropic support or those with severe volume overload, we withhold therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who are not treated with beta blocker therapy chronically, we do not initiate a beta blocker in the early management of acute HF. However, a small randomized trial and a larger observational study found that initiation of therapy prior to hospital discharge in stable patients improves long-term beta blocker compliance without an increase in side effects or drug discontinuation, so initiation prior to discharge is recommended in stable patients. Prior to initiation of therapy, the patient should have no or minimal evidence of fluid retention and should not have required recent intravenous inotropic therapy. Beta blocker therapy should start with low doses. Particular caution is indicated in patients who have required inotropes during their hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link&amp;anchor=H8#H8\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Initiation of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27389179\">",
"    <span class=\"h2\">",
"     Aldosterone antagonist therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have demonstrated that aldosterone antagonist therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) reduces mortality when included in long-term management of selected patients with systolic heart failure who can be carefully monitored for serum potassium and renal function. These include patients who have NYHA functional class II HF and an LVEF &le;30 percent; or NYHA functional class III to IV HF and an LVEF &le;35 percent; and patients post ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus. The serum potassium should be &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and eGFR should be &ge;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients already taking an aldosterone antagonist, such therapy can generally be continued during an episode of acute decompensation, with appropriate monitoring of blood pressure, renal function, and electrolytes. For patients not taking an aldosterone antagonist who have an indication for therapy, we favor initiation prior to discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15438955\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis against venous thromboembolism (deep vein thrombosis and pulmonary embolism) with low-dose unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is indicated in patients admitted with ADHF who are not already anticoagulated and have no contraindication to anticoagulation. In patients admitted with ADHF who have a contraindication to anticoagulation, venous thromboembolism prophylaxis with a mechanical device (eg, intermittent pneumatic compression device) is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Morphine sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    therapy in ADHF. Morphine reduces patient anxiety and decreases the work of breathing. These effects diminish central sympathetic outflow, leading to arteriolar and venous dilatation with a resultant fall in cardiac filling pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, retrospective studies have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    administration for ADHF is associated with increased frequency of mechanical ventilation and in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], although a causal relationship has not been established. In one retrospective analysis, morphine was administered in 14 percent of 150000 ADHF hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/35\">",
"     35",
"    </a>",
"    ]. Morphine use was associated with more frequent mechanical ventilation, longer hospitalizations, more intensive care unit admissions, and greater mortality. After risk adjustment and exclusion of ventilated patients, morphine remained an independent predictor of mortality (OR 4.8, 95% CI 4.52 to 5.18, p &lt;0.001). Although risk adjustment in this study may not have been adequate, these results raise concern about the safety of morphine in this population.",
"   </p>",
"   <p>",
"    The 2008 ESC guidelines for the treatment of acute heart failure include consideration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    as an ungraded recommendation noting that supporting data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/36\">",
"     36",
"    </a>",
"    ]. Morphine therapy is not mentioned in the 2010 HFSA guidelines on management of ADHF or in the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update.",
"   </p>",
"   <p>",
"    Given the limited evidence of benefits and potential risks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , we suggest generally avoiding morphine therapy in the treatment of ADHF without acute MI.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    in patients with ADHF who have an acute MI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\", section on 'Morphine sulfate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADDITIONAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above treatments, several additional options and considerations may be relevant to selected patients. Management of refractory heart failure is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mechanical cardiac assistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cardiogenic pulmonary edema who are also in cardiogenic shock should be considered candidates for mechanical circulatory support. These patients usually have a cardiac index less than 2.0",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2, a systolic arterial pressure below 90 mmHg, and a pulmonary capillary wedge pressure above 18 mmHg, despite adequate pharmacologic therapy.",
"   </p>",
"   <p>",
"    The two major mechanical modalities used in this setting are intraaortic balloon counterpulsation and an internally implanted left ventricular assist device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration is an effective method of fluid removal with advantages that include adjustable fluid removal volumes and rates, no effect on serum electrolytes, and decreased neurohormonal activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ADHF accompanied by renal insufficiency or diuretic resistance may benefit from ultrafiltration. Most studies have used a peripherally inserted ultrafiltration device that does not require central access, specialized nursing, or ICU admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4,37\">",
"     4,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of ultrafiltration in patients with ADHF has been evaluated in several randomized trials:",
"    <br/>",
"   </p>",
"   <p>",
"    In the RAPID-CHF trial, 40 patients with ADHF and renal insufficiency (serum creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticipated diuretic resistance (high daily oral diuretic doses) were randomly assigned to receive usual care with or without ultrafiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/38\">",
"     38",
"    </a>",
"    ]. Ultrafiltration was associated with significant increases in fluid removal after 24 hours (4650 versus 2838 mL without ultrafiltration) and weight loss (2.5 versus 1.9 kg) without a difference in serum creatinine.",
"   </p>",
"   <p>",
"    In the larger UNLOAD trial, 200 patients hospitalized for ADHF were randomly assigned to ultrafiltration or to standard care including intravenous diuretics during the admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/31\">",
"     31",
"    </a>",
"    ]. Renal dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticipated diuretic resistance were not entry criteria. Thus, this study included a less selected group of HF patients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 48 hours, patients assigned to ultrafiltration had a significantly greater fluid loss (4.6 versus 3.3 liters with standard care). This difference may in part reflect the relatively modest level of diuretic therapy used in the standard care arm.",
"     </li>",
"     <li>",
"      At 90 days, patients assigned to ultrafiltration had significantly fewer HF rehospitalizations than patients assigned to standard care (0.22 versus 0.46 admissions per patient) and fewer unscheduled clinic visits (21 versus 44 percent with standard care).",
"     </li>",
"     <li>",
"      The rates of adverse events were similar in the two groups, although there was a higher incidence of bleeding in the standard care arm. There was no difference in serum creatinine, as was also found in a smaller trial with detailed assessment of renal hemodynamics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In CARRESS-HF, 188 patients with ADHF, worsened renal function (defined as an increase in the serum creatinine level of at least 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [26.5",
"    <span class=\"nowrap\">",
"     &mu;mol/L]),",
"    </span>",
"    and persistent congestion were randomly assigned to either stepped pharmacology therapy or ultrafiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/40\">",
"     40",
"    </a>",
"    ]. The stepped pharmacologic care algorithm included bolus plus high doses of continuous infusion loop diuretic, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    , and selective use of inotrope or vasodilator therapy. The primary endpoint was the bivariate change in the serum creatinine level and body weight from baseline to 96 hours after enrollment. Ultrafiltration was inferior to pharmacologic therapy with respect to the primary end point due to increase in serum creatinine in the ultrafiltration group in contrast to a fall in mean serum creatinine in the pharmacologic therapy group (+0.23&plusmn;0.70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [+20.3&plusmn;61.0",
"    <span class=\"nowrap\">",
"     &mu;mol/L]",
"    </span>",
"    versus -0.04&plusmn;0.53",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-3.5&plusmn;46.9",
"    <span class=\"nowrap\">",
"     &mu;mol/L]).",
"    </span>",
"    There was no significant difference in weight loss at 96 hours between the ultrafiltration and pharmacologic therapy groups (5.7&plusmn;3.9 kg [12.6&plusmn;8.5 lb] and 5.5&plusmn;5.1 kg [12.1&plusmn;11.3] lb]). A higher percentage of patients in the ultrafiltration group had serious adverse events (eg, heart failure, renal failure, anemia or thrombocytopenia, electrolyte disorder, hemorrhage, pneumonia, sepsis) (72 versus 57 percent).",
"   </p>",
"   <p>",
"    Thus, while ultrafiltration was an effective method for fluid volume removal, which provided similar amounts of weight loss to stepped pharmacologic therapy, it was inferior to stepped pharmacologic therapy for preservation of renal function at 96 hours and was associated with a higher rate of adverse events. &nbsp;",
"   </p>",
"   <p>",
"    Ultrafiltration is reserved for patients who do not achieve an adequate response to an aggressive diuretic regimen. This recommendation is consistent with the 2005 (with 2009 update)",
"    <span class=\"nowrap\">",
"     ACC/AHA,",
"    </span>",
"    2008 ESC and 2010 HFSA heart failure guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2,4,36\">",
"     2,4,36",
"    </a>",
"    ]. Consultation with a kidney specialist may be appropriate prior to opting for a mechanical strategy of fluid removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin receptor antagonists have been investigated as an adjunct to diuretics and other standard therapies in patients with ADHF as a means of countering arterial vasoconstriction, hyponatremia, and water retention. However, such treatment is controversial and not included in the HFSA guidelines. The 2008 ESC guidelines suggest consideration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    for HF patients with hyponatremia in an ungraded recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/36\">",
"     36",
"    </a>",
"    ]. Tolvaptan is the most studied agent in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=see_link\">",
"     \"Possibly effective emerging therapies for heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link&amp;anchor=H9#H9\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Vasopressin-receptor antagonists'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=see_link\">",
"       \"Patient information: When your lungs fill with fluid (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the management of patients with ADHF. They are generally in agreement with those published in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines with 2009 focused update, the 2010 HFSA ADHF guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"     2",
"    </a>",
"    ] and the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    STEMI guidelines with 2007 focused update and the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    NSTEMI guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4,16,41,42\">",
"     4,16,41,42",
"    </a>",
"    ]. A table to assist with emergency management of ADHF is provided (",
"    <a class=\"graphic graphic_table graphicRef75041 \" href=\"mobipreview.htm?20/58/21421\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Initial therapy includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supplemental oxygen and assisted ventilation if necessary",
"     </li>",
"     <li>",
"      Diuresis with an intravenous loop diuretic",
"     </li>",
"     <li>",
"      Vasodilator therapy in patients without hypotension (eg, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In selected patients with severe or refractory symptoms, the following additional therapies may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous positive inotropic agents",
"     </li>",
"     <li>",
"      Mechanical cardiac assistance",
"     </li>",
"     <li>",
"      Ultrafiltration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Oxygen and ventilatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF and a decreased oxygen saturation should be treated with supplemental oxygen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with significant hypoxia or respiratory distress are generally treated with high flow oxygen via a nonrebreather facemask; later oxygen is titrated to patient comfort and an oxygen saturation of at least 90 percent.",
"     </li>",
"     <li>",
"      For patients with ADHF and respiratory failure, we recommend a trial of noninvasive positive pressure ventilation (NPPV) if emergent intubation is not indicated, no contraindications to NPPV exist (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 2",
"      </a>",
"      ), and personnel with experience in NPPV are available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Supplemental oxygen and assisted ventilation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H16#H16\">",
"       \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Cardiogenic pulmonary edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with respiratory failure due to ADHF who fail NPPV, do not tolerate NPPV, or have contraindications to NPPV (",
"      <a class=\"graphic graphic_table graphicRef60442 \" href=\"mobipreview.htm?16/54/17259\">",
"       table 2",
"      </a>",
"      ) require endotracheal intubation for conventional mechanical ventilation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"       \"Overview of mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fluid removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF and pulmonary edema have symptomatic relief and improved oxygenation with fluid removal. Diuretics are recommended except in patients with severe hypotension or cardiogenic shock.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with ADHF and fluid overload, we recommend that initial therapy include an intravenous loop diuretic (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diuretics'",
"      </a>",
"      above.) Dosing is individualized, determined largely by the patient's renal function and prior diuretic exposure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diuretic dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Effects on renal function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bolus dosing with intravenous loop diuretics achieves adequate diuresis in most patients. Determination of effective diuretic dosing should be confirmed by demonstration of a negative fluid balance. For patients who do not have adequate fluid removal with this approach, options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuous infusion of loop diuretic",
"     </li>",
"     <li>",
"      Addition of a thiazide diuretic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of aldosterone antagonists is discussed below. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Systolic dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ultrafiltration is an option for patients refractory to diuretic therapy. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Ultrafiltration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilators, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , can reduce filling pressures, improve symptoms, and facilitate diuresis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Vasodilator therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with acute decompensated heart failure who are not hypotensive, we suggest the use of a vasodilator in addition to diuretic therapy with close hemodynamic monitoring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vasodilator therapy'",
"      </a>",
"      above.) When using vasodilators in patients with ADHF, we favor the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      is generally recommended. Nitrate administration is contraindicated after use of PDE-5 inhibitors such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In selected cases when there is a need for significant afterload reduction (eg, hypertensive emergency, acute aortic or mitral regurgitation), we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , although the risk of cyanide or thiocyanate toxicity limit its use.",
"     </li>",
"     <li>",
"      For most patients hospitalized with acute heart failure (HF), we recommend",
"      <strong>",
"       not",
"      </strong>",
"      treating with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In carefully selected patients with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of nesiritide may be helpful as an alternative to other vasodilator therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ). Nesiritide has a longer effective half-life than nitroglycerin or nitroprusside, so side effects such as hypotension may persist longer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=see_link&amp;anchor=H7#H7\">",
"       \"Nesiritide in the treatment of acute decompensated heart failure\", section on 'Use'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Vasodilator therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Inotropes and mechanical cardiac support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF and systolic dysfunction who are hypotensive or who remain in pulmonary edema despite oxygen, diuresis, and, if tolerated, vasodilators, may benefit from intravenous inotropic support and may require mechanical cardiac support. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Inotropic agents'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Mechanical cardiac assistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31640487\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected cases, vasopressors can be used with appropriate hemodynamic monitoring as a temporizing measure restricted to patients with persistent hypotension with evidence of symptoms or signs of end-organ hypoperfusion despite optimization of filling pressures and consideration of the use of inotropic agents. (See",
"    <a class=\"local\" href=\"#H14168249\">",
"     'Vasopressor therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     ACE inhibitors/ARBs and beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors, ARBs, and beta blockers require special consideration in patients with decompensated heart failure. The approach to their use depends upon whether the patient has primarily systolic or diastolic dysfunction. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Systolic dysfunction'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H35\">",
"     'Diastolic dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic HF due to systolic dysfunction the long-term use ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs",
"    </span>",
"    and beta blockers reduces mortality, but there are short-term risks to the use of these medications in the setting of acute HF. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'ACE inhibitors and ARBs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We approach the use of these medications in this setting in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are not already taking an ACE inhibitor or ARB, we suggest that they NOT be initiated at the time of presentation with an episode of ADHF (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An oral ACE inhibitor or ARB can usually be started within 24 to 48 hours, once the patient is hemodynamically stable.",
"     </li>",
"     <li>",
"      For patients who are not already taking a beta blocker, we suggest that they NOT be initiated at the time of presentation with an episode of ADHF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Beta blockers are generally started later than ACE inhibitors or ARBs, when the patient is euvolemic, usually shortly before discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the initiation of these medications, including dosing and sequence of initiation, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are already taking an ACE inhibitor or ARB, we suggest that maintenance of oral therapy be cautiously continued (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the dose should be decreased or the drug discontinued if hypotension, acute renal failure, or hyperkalemia is present. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Continued therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are already taking a beta blocker, management depends upon the severity of HF decompensation and hemodynamic instability (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Beta blockers'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with severe decompensation (eg, severe volume overload",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      requiring inotropic support), we suggest withholding beta blockers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with moderate-to-severe decompensation, we suggest decreasing or withholding beta blocker therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with mild decompensation without hypotension or evidence of hypoperfusion, we suggest continuation of beta blocker as tolerated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aldosterone antagonist therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) reduces mortality when included in long-term management of selected patients with systolic HF who can be carefully monitored for serum potassium and renal function. In patients already taking an aldosterone antagonist, such therapy can generally be continued during an episode of acute decompensation, with appropriate monitoring of blood pressure, renal function, and electrolytes. For patients not taking an aldosterone antagonist who have an indication for therapy, we favor initiation prior to discharge. (See",
"    <a class=\"local\" href=\"#H27389179\">",
"     'Aldosterone antagonist therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients with ADHF are treated similarly whether they have primarily systolic or diastolic dysfunction. However, in patients with diastolic dysfunction, long-term use of ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs",
"    </span>",
"    and beta blockers does not provide the same benefit as in patients with HF due to systolic dysfunction. The efficacy of aldosterone antagonist therapy in this population is under investigation. On the other hand, the short term risks of beta blockers are less concerning and treatment of hypertension and tachycardia are particularly important. Thus, antihypertensive agents and beta blockers may be useful in acute as well as chronic HF in patients with primarily diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15439008\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism prophylaxis is indicated in patients hospitalized with ADHF. (See",
"    <a class=\"local\" href=\"#H15438955\">",
"     'Venous thromboembolism prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence of benefit (eg, reduced patient anxiety and decreased worked of breathing) from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    and there is potential risk (eg, increased need for ventilatory support), so we suggest avoiding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    therapy in patients with ADHF without acute myocardial infarction. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Morphine sulfate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Management of ADHF in MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific considerations apply to treatment of ADHF during acute MI, particularly the importance of revascularization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/1\">",
"      Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/2\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/3\">",
"      Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009; 2:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/4\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/5\">",
"      Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation 1968; 37:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/6\">",
"      Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/7\">",
"      Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; :CD003178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/8\">",
"      Dikshit K, Vyden JK, Forrester JS, et al. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973; 288:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/9\">",
"      Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/10\">",
"      Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000; 36:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/11\">",
"      Palmer RF, Lasseter KC. Drug therapy. Sodium nitroprusside. N Engl J Med 1975; 292:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/12\">",
"      Packer M, Meller J, Medina N, et al. Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. N Engl J Med 1979; 301:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/13\">",
"      O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/14\">",
"      Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112:3958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/15\">",
"      Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J 1994; 15 Suppl B:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/16\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/17\">",
"      Gage J, Rutman H, Lucido D, LeJemtel TH. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986; 74:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/18\">",
"      Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991; 121:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/19\">",
"      Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/20\">",
"      Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/21\">",
"      Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/22\">",
"      Simonton CA, Chatterjee K, Cody RJ, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/23\">",
"      Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991; 121:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/24\">",
"      Liang CS, Sherman LG, Doherty JU, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 1984; 69:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/25\">",
"      Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/26\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/27\">",
"      Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006; 47:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/28\">",
"      Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 2007; 9:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/29\">",
"      Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/30\">",
"      Orso F, Baldasseroni S, Fabbri G, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail 2009; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/31\">",
"      Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/32\">",
"      Hsu HO, Hickey RF, Forbes AR. Morphine decreases peripheral vascular resistance and increases capacitance in man. Anesthesiology 1979; 50:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/33\">",
"      Pur-Shahriari AA, Mills RA, Hoppin FG Jr, Dexter L. Comparison of chronic and acute effects of morphine sulfate on cardiovascular function. Am J Cardiol 1967; 20:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/34\">",
"      Sosnowski MA. Review article: lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema. Emerg Med Australas 2008; 20:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/35\">",
"      Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008; 25:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/36\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/37\">",
"      Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/38\">",
"      Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/39\">",
"      Rogers HL, Marshall J, Bock J, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 2008; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/40\">",
"      Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/41\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/56/34698/abstract/42\">",
"      Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117:296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3450 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34698=[""].join("\n");
var outline_f33_56_34698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Supplemental oxygen and assisted ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diuretic dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effects on renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inadequate response to diuretic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sodium and fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vasodilator therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nitroprusside",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nesiritide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADDITIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Continued therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inotropic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Specific agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14168249\">",
"      Vasopressor therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27389179\">",
"      Aldosterone antagonist therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15438955\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Morphine sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADDITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mechanical cardiac assistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Oxygen and ventilatory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fluid removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Inotropes and mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31640487\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ACE inhibitors/ARBs and beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15439008\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Morphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Management of ADHF in MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/58/21421\" title=\"table 1\">",
"      Rapid overview acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/54/17259\" title=\"table 2\">",
"      Contraindications to NPPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=related_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_56_34699="Relapsing fever Borrelia spp";
var content_f33_56_34699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Borrelia species causing tick-borne relapsing fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tick vector",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. hermsii",
"       </td>",
"       <td>",
"        Ornithodoros hermsii",
"       </td>",
"       <td>",
"        Western North America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. turicatae",
"       </td>",
"       <td>",
"        O. turicatae",
"       </td>",
"       <td>",
"        Southwestern North America and northern Mexico",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. venezuelensis",
"       </td>",
"       <td>",
"        O. rudis",
"       </td>",
"       <td>",
"        Central America and northern South America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. hispanica",
"       </td>",
"       <td>",
"        O. erraticus",
"       </td>",
"       <td>",
"        Iberian peninsula and northwestern Africa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. crocidurae",
"       </td>",
"       <td>",
"        O. erraticus",
"       </td>",
"       <td>",
"        North Africa and Mediterranean region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. duttonii",
"       </td>",
"       <td>",
"        O. moubata",
"       </td>",
"       <td>",
"        Central, eastern and southern Africa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. persica",
"       </td>",
"       <td>",
"        O. tholozani",
"       </td>",
"       <td>",
"        Western China, India, central Asia, Middle East",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. latyschewii",
"       </td>",
"       <td>",
"        O. tartakovskyi",
"       </td>",
"       <td>",
"        Tajikistan, Uzbekistan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34699=[""].join("\n");
var outline_f33_56_34699=null;
var title_f33_56_34700="Life expectancy by age";
var content_f33_56_34700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Life expectancy by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Ages in years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        70",
"       </td>",
"       <td class=\"subtitle2\">",
"        75",
"       </td>",
"       <td class=\"subtitle2\">",
"        80",
"       </td>",
"       <td class=\"subtitle2\">",
"        85",
"       </td>",
"       <td class=\"subtitle2\">",
"        90",
"       </td>",
"       <td class=\"subtitle2\">",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Women - years of expected life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Top 25th percentile",
"       </td>",
"       <td class=\"centered\">",
"        21.3",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        9.6",
"       </td>",
"       <td class=\"centered\">",
"        6.8",
"       </td>",
"       <td class=\"centered\">",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td class=\"centered\">",
"        15.7",
"       </td>",
"       <td class=\"centered\">",
"        11.9",
"       </td>",
"       <td class=\"centered\">",
"        8.6",
"       </td>",
"       <td class=\"centered\">",
"        5.9",
"       </td>",
"       <td class=\"centered\">",
"        3.9",
"       </td>",
"       <td class=\"centered\">",
"        2.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lowest 25th percentile",
"       </td>",
"       <td class=\"centered\">",
"        9.5",
"       </td>",
"       <td class=\"centered\">",
"        6.8",
"       </td>",
"       <td class=\"centered\">",
"        4.6",
"       </td>",
"       <td class=\"centered\">",
"        2.9",
"       </td>",
"       <td class=\"centered\">",
"        1.8",
"       </td>",
"       <td class=\"centered\">",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Men - years of expected life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Top 25th percentile",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"       <td class=\"centered\">",
"        14.2",
"       </td>",
"       <td class=\"centered\">",
"        10.8",
"       </td>",
"       <td class=\"centered\">",
"        7.9",
"       </td>",
"       <td class=\"centered\">",
"        5.8",
"       </td>",
"       <td class=\"centered\">",
"        4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td class=\"centered\">",
"        12.4",
"       </td>",
"       <td class=\"centered\">",
"        9.3",
"       </td>",
"       <td class=\"centered\">",
"        6.7",
"       </td>",
"       <td class=\"centered\">",
"        4.7",
"       </td>",
"       <td class=\"centered\">",
"        3.2",
"       </td>",
"       <td class=\"centered\">",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lowest 25th percentile",
"       </td>",
"       <td class=\"centered\">",
"        6.7",
"       </td>",
"       <td class=\"centered\">",
"        4.9",
"       </td>",
"       <td class=\"centered\">",
"        3.3",
"       </td>",
"       <td class=\"centered\">",
"        2.2",
"       </td>",
"       <td class=\"centered\">",
"        1.5",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34700=[""].join("\n");
var outline_f33_56_34700=null;
var title_f33_56_34701="Contents: Dermatologic disease";
var content_f33_56_34701=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Dermatologic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dermatologic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/18/21802\">",
"           Cutaneous manifestations of internal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/39/14970\">",
"           Epidemiology and clinical features of basal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/56/25482\">",
"           Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/8/5258\">",
"           Onychomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/11/25786\">",
"           Oral lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/20/16713\">",
"           Skin examination and clinical features of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/15/30968\">",
"           Treatment of actinic keratosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-3AFFECA29B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f33_56_34701=[""].join("\n");
var outline_f33_56_34701=null;
var title_f33_56_34702="HgbA1c and cholesterol orlistat";
var content_f33_56_34702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Metabolic benefits of orlistat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean (&plusmn;SE) changes in HbA1c values (left panel) and serum total cholesterol concentrations (right panel) after treatment with orlistat or placebo for one year in patients with type 2 diabetes. Among patients who lost weight (which was more prominent and common in the orlistat group), orlistat therapy was associated with significantly greater improvements in HbA1c and serum total cholesterol. To convert the changes in serum cholesterol values to mg/dL, divide by 0.026.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34702=[""].join("\n");
var outline_f33_56_34702=null;
var title_f33_56_34703="Management algorithm of GERD patient who failed PPI once daily";
var content_f33_56_34703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Management algorithm of GERD patient who failed PPI once daily",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 538px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Management algorithm of gastroesophageal reflux disease (GERD) patient who failed PPI once daily (complete or partial*).",
"    <div class=\"footnotes\">",
"     PPI: proton pump inhibitor; SSRIs: selective serotonin reuptake inhibitors; TLESR: transient lower esophageal sphincter relaxation; H2RA: histamine 2 receptor antagonist.",
"     <br>",
"      * Partial or incomplete relief of symptoms.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol 2010; 24:923. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_56_34703=[""].join("\n");
var outline_f33_56_34703=null;
